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Abstract 
Hypoxia and inflammation have been associated with carcinogenesis. Both 
microenvironments induce alterations in central carbon metabolism, leading to a more 
cancerous metabolic phenotype. Even in the presence of oxygen, many cancer cells adapt 
their cellular metabolism towards a hypoxia-like metabolic phenotype, including increased 
glucose uptake, higher glycolytic flux, increased lactate production, and decreased O2 
consumption, a phenomenon known as Warburg effect. In part this response is mediated by 
hypoxia inducible factor-1α (HIF-1α), a transcriptional key regulator of the cellular response 
to hypoxia. Using stable isotope assisted metabolomics, I investigated the role of HIF-1α in 
oncostatin M (OSM) mediated metabolic reprogramming of the human hepatocyte cell line 
PH5CH8. I show that under normoxia, OSM-induced up-regulation of HIF-1α results in a 
hypoxia-like metabolic phenotype. Although, glucose uptake and lactate secretion are only 
slightly increased, stable isotope labelling revealed drastic changes in intracellular metabolic 
fluxes. In particular, I show that OSM suppresses glucose and glutamine oxidation in the 
tricarboxylic acid cycle via pyruvate dehydrogenase kinase 1 (PDK1) mediated inhibition of 
pyruvate dehydrogenase. This finding highlights the role of PDK1 as one of the key 
enzymes, responsible for the OSM-induced metabolic phenotype. As a result of the impaired 
glucose oxidation, PH5CH8 show higher rates of reductive glutamine metabolism.  
Finally, I demonstrate that HIF-1α is critical for OSM-mediated metabolic reprogramming. 
Silencing HIF-1α almost completely impeded OSM-induced metabolic changes, connecting 
HIF-1α, inflammation, and cancer cell metabolism. 
Altogether, the results obtained in this thesis might provide a causal link between chronic 
inflammation and malignant cellular transformation. 
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1 Introduction 
1.1 Biological background 
1.1.1 Hepatocellular carcinoma 
Liver cancer is the sixth most common cancer and the third cause of cancer-related death 
worldwide (1). Over 90% of primary liver cancers are hepatocellular carcinomas (HCC) (1). 
HCC development can be the consequence of liver cirrhosis caused by alcoholic liver 
disease, non-alcoholic fatty liver disease (hepatosteatosis), or aflatoxin exposure (Aspergillus 
flavus) (1). Most HCCs are preceded by chronic inflammation due to viral hepatitis infections 
(hepatitis B and C virus), suggesting that an inflammatory microenvironment promotes HCC 
development (1). Prominent mediators of this immune response are interleukin (IL)-6-type 
cytokines. Besides their regulatory role in chronic inflammation and immune response, IL-6-
type cytokines are key players in the regulation of cancer development and progression (2).  
 
1.1.2 IL-6-type cytokine signalling 
The family of IL-6-type cytokines includes IL-6, interleukin-11 (IL-11), oncostatin M (OSM), 
ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), 
and cardiotrophin-like cytokine (CLC) (3). IL-6-type cytokines activate target genes involved 
in cell differentiation, survival, apoptosis, and proliferation (3). They initiate the Janus kinase/ 
Signal transducer and activator of transcription 3 (JAK/STAT3) signalling cascade. Ligand-
binding induces membrane receptor homo- or heterodimerization. The dimeric receptors are 
composed of a gp130 and a ligand specific subunit (4), including non-signalling α-receptors 
(IL-6-receptor α, IL-11-receptor α, and CNTF receptor α) or signal transducing receptors 
(gp130, LIF-receptor, and OSM-receptor) (3,4).  
 
Upon ligand binding, activated JAKs bind the membrane-proximal region of the dimeric 
cytokine receptor, leading to phosphorylation at tyrosine residues (3,4). Cytokine receptor 
phosphorylation results in the activation of multiple major signalling pathways, including 
STAT3, phosphatidylinositol-3-kinase (PI3K)/Akt(5), and the mitogen-activated protein 
kinases (MAPK) pathway (3,4). All IL-6-type cytokines induce STAT3 by the following 
activation mechanism: monomeric STAT3 is recruited to the activated IL-6-type cytokine 
receptor (3) where it binds to the phosphotyrosine sites via the src homology (SH)-2 domain, 
resulting in tyrosine phosphorylation on the C-terminal domain of STAT3. The SH-2 domain 
of one active STAT3 monomer and the phosphotyrosine of the other active monomer interact 
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and form a dimer. As a consequence of dimerization, the STAT3 homodimer translocates 
into the nucleus where it binds to transcription factor binding sides of genes involved in cell 
survival and proliferation (3,4,6). Figure 1.1 depicts the OSM-mediated STAT3 signalling 
pathway as an example of IL-6 type cytokine signalling.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 OSM activates the JAK/STAT pathway. OSM binds to the LIF-receptor 
or to the OSM-receptor associated to a gp130 monomer. Upon ligand binding, the 
OSM-R and gp130 dimerize. Subsequently, JAKs are activated and bind to the 
cytokine receptor, leading to its phosphorylation, which in turn activates signal 
transducers and activators of transcription 3 (STAT3). The SH-2 domain of one active 
STAT3 monomer and the phosphotyrosine of the other active monomer interact and 
form a dimer. The STAT3 homodimer translocates into the nucleus where it binds to 
responsive elements on gene promoters.  
 
 
1.1.3 STAT3 signalling 
The pro-oncogenic transcription factor STAT3 exerts a central role in pro-inflammatory 
signalling downstream of IL-6-type cytokine stimulation (7). Aberrant STAT3 activation is 
commonly observed in human cancers, including leukemia’s, lymphomas, lung, gastric, 
hepatocellular, colorectal, and prostate cancer (6) and consists a point of convergence 
between pro-inflammatory signalling and cancer development (7). Constitutively activated 
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STAT3 plays an important role in tumour-promoting inflammation and regulates numerous 
genes involved in cancer cell progression, proliferation (e.g. c-myc, cyclin D1), invasion 
(matrix metalloproteinase-2), cell survival (e.g. survivin, bcl-xl, myeloid cell leukemia-1, B-cell 
lymphoma-2 and cIAP2) and angiogenesis (vascular endothelial growth factor (VEGF)) (7). 
Beside IL-6-type cytokines, growth factors (e.g. TGFα, EGF, G-CSF, M-CSF or GM-CSF), 
oncogenic proteins, carcinogens (e.g. cigarette smoke) and environmental stress can 
activate the STAT3 signalling cascade (6).  
Recently, it was shown that the IL-6-type cytokine OSM induces the expression of hypoxia 
inducible factor-1α (HIF-1α) in immortalized hepatocytes and hepatocellular carcinoma cells 
(8). Vollmer and colleagues showed that HIF-1α mRNA and HIF-1α protein levels are 
upregulated under normoxic in vitro conditions (21% O2) in response to the OSM mediated 
STAT3 activation (8). In contrast to hypoxia, OSM signalling does not contribute to an 
increased HIF-1α stability, but solely enhances HIF-1α expression (8). 
 
1.1.4 Regulation of HIF 
HIFs, including HIF-1,-2, and -3, are part of the basic helix-loop-helix-PAS (bHLH/ PAS) 
(9,10) family of transcription factors and are primarily regulated post-translationally (11). HIF-
1 is a heterodimer that consists of two subunits, the constitutively expressed HIF-1β subunit 
and the O2-dependant HIF-1α subunit (11). As the key regulator of the cellular response to 
low oxygen levels, HIF-1 is essential for cell survival under hypoxic conditions (9). The HIF-
1α subunit is stabilized under hypoxic conditions whereas it is continuously degraded in a 
normoxic environment.  
HIF-1α is constitutively expressed but its stability is negatively regulated by O2-dependent 
prolyl 4-hydroxylase domain proteins (PHD) (Figure 1.2). Under normal oxygen tensions, 
PHD hydroxylates the two conserved proline residues Pro402 and Pro564 within the oxygen 
dependent degradation domain (ODDD) of HIF-1α. This hydroxylation reaction depends on 
the availability of molecular oxygen (O2), 2-oxoglutarate (2-OG), as well as iron (Fe2+) and 
ascorbate (12). Subsequently the von Hippel Lindau tumour suppressor protein (VHL) binds 
the hydroxylated prolines residues leading to HIF-1α polyubiquitination and proteasome-
mediated degradation (9) (Figure 1.2). Degradation of HIF-1α is extremely rapid with a half-
life of less than 5 minutes. However, under hypoxic conditions the activity of PHD, due to 
lack of O2, is suppressed and HIF-1α is stabilized (11). 
Under normoxic condition, the transcriptional activity of HIF-1α is regulated by the factor 
inhibiting HIF (FIH) which hydroxylates the asparagine residue 803 (Asn803) and thereby 
inhibits the binding of the transcriptional co-activator p300/CBP. HIF-1α can be stabilized and 
active under normoxic conditions. The TCA cycle intermediates succinate and fumarate have 
been reported to increase HIF-1α stability by inhibiting PHD activity. Both intermediates bind 
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to the 2-OG- or Fe2+-binding sites of PHD, thereby blocking the interaction with proline in the 
ODDD of HIF-1α (12). Mutations in the succinate dehydrogenase (SDH) result in an 
accumulation of succinate, inhibiting PHD in the cytosol (12). Furthermore, it has been 
shown that in renal cell carcinoma and congenital erythrocytosis, mutations in VHL and PHD 
lead to an up-regulation of HIF-1α (13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 HIF-1α regulation under normoxic conditions. In normoxia HIF-1α is 
hydroxylated by PHD in the presence of O2, Fe2+, 2-oxoglutarate (2-OG), and 
ascorbate. FIH hydroxylates the asparagine residue to inhibit the binding of the 
transcriptional co-activator p300/CBP. Hydroxylated HIF-1α is recognized by von VHL 
protein together with ubiquitin ligase complex, leading to its polyubiquitination and 
targeting it for proteasome-mediated degradation. 
 
Once HIF-1α is stabilized, it translocates to the nucleus where HIF-1α and HIF-1β form a 
heterodimer and recruit other transcriptional co-activators such as p300/CBP histone 
acetyltransferase, steroid receptor coactivator-1 (SRC-1) family or nuclear redox regulator 
(Ref-1). The HIF-1-p300/CBP complex recognizes the consensus nucleotide sequence 5’-
RCGTG-3’ of hypoxia-response elements (HREs) within the promoter regions of numerous 
target genes (10,14) and promotes their transcription. HIF-1α activates the transcription of 
genes encoding for the vascular endothelial growth factor (VEGF), plasminogen activator 
inhibitor 1 (PAI1), which are crucial for angiogenesis and tissue remodelling, and 
erythropoietin (EPO), involved in erythropoiesis. Moreover, HIF-1α regulates the expression 
of numerous genes involved in the adaptation of the cellular metabolism to low oxygen 
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tensions (15). Figure 1.3 gives an overview of the nuclear translocation, heterodimerization 
and lists the important HIF-1α target genes. 
 
Figure 1.3 HIF-1α regulation in response to hypoxia. Under hypoxic conditions, 
proline and asparagine hydroxylations are inhibited. VHL cannot bind and target HIF-
1α for proteasomal degradation, which leads to HIF-1α accumulation and 
translocation to the nucleus. The constitutively expressed HIF-1β subunit translocates 
to the nucleus to form a heterodimer with HIF-1α, which recruits other transcriptional 
co-activators such as p300/CBP. The complex binds to HREs within the promoters of 
target genes involved in angiogenesis, glucose metabolism mitochondrial autophagy 
and erythropoiesis.  
 
1.1.5 Effects of HIF-1α on cellular metabolism 
HIF-1α is indispensable to adapt cellular metabolism to hypoxic environments. It is well 
established that HIF-1α orchestrates the expression of several genes that drives the change 
from oxidative phosphorylation towards a more glycolytic metabolic phenotype (10) (Figure 
1.3). HIF-1α regulates the expression of glucose transporters (e.g., GLUT1 and GLUT3) to 
increase glucose import into the cytoplasm and promotes higher rates of glycolysis by up-
regulating glycolytic genes, including lactate dehydrogenase A (LDHA), phosphoglycerate 
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kinase 1 (PGK1) and hexokinase 1 (HK1), promoting high rates of glycolysis (Figure 1.4). 
HIF-1α indirectly reduces mitochondrial pyruvate oxidation through the up-regulation of 
pyruvate dehydrogenase kinase 1 (PDK1). In turn, PDK1 phosphorylates and inactivates 
pyruvate dehydrogenase complex (PDH), which oxidizes pyruvate to acetyl-CoA (Figure 1.5). 
As a result the entry of pyruvate into the TCA cycle is diminished, leading to reduced 
mitochondrial oxidative phosphorylation. As a result of increased glycolysis, increased LDH 
and reduced PDH activity, the glycolytic flux is deviated and pyruvate is converted to lactate 
(10,16,17). 
As a consequence of reduced PDH activity under hypoxic conditions, citrate production from 
glucose-derived acetyl-CoA is drastically reduced. However, citrate is an important 
metabolite required to transport acetyl-CoA moieties from mitochondria to the cytosol, where 
it is an important precursor for fatty acid synthesis and protein acetylation (18). As the citrate 
pool is drastically reduced under hypoxic conditions, the cellular metabolism needs to be 
adapted in order to ensure proliferation and growth (10).  
Besides glucose, the amino acid glutamine is required as a major carbon source in 
eukaryotic cells. At normal oxygen tension, glutamine is required to support cell growth and 
division (19,20). Glutaminase catalyses the conversion of glutamine to glutamate, which is 
converted to α-ketoglutarate via glutamate dehydrogenase. Thereby, glutamine-derived α-
ketoglutarate can be oxidatively or reductively metabolized in the TCA cycle (Figure 1.5). In 
oxidative glutamine metabolism, α-ketoglutarate is oxidized to succinate and eventually 
converted to citrate in the TCA cycle. This includes citrate synthase, which condenses acetyl-
CoA and oxaloacetate to citrate. 
Since citrate production from glucose-derived acetyl-CoA is drastically reduced in hypoxic 
conditions, citrate can also be generated from isocitrate by aconitase (Figure 1.5). Therefore, 
isocitrate is produced from α-ketoglutarate, catalysed by isocitrate dehydrogenase (IDH). 
The reaction of IDH is reversible and leads to the possibility of citrate generation from 
glutamine-derived α-ketoglutarate, without the necessity of free acetyl-CoA (Figure 1.5). For 
that, glutamine-derived α-ketoglutarate is reductively carboxylated to isocitrate by IDH and 
eventually converted to citrate. Conditions lowering mitochondrial citrate levels such as 
hypoxia or complex 1 inhibition have been shown to increase reductive α-ketoglutarate 
carboxylation by mass action (19). This metabolic flux is of critical importance for lipid 
synthesis, when acetyl-CoA availability becomes scarce (19,21). 
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Figure 1.4 Simplified scheme of the glycolysis. Metabolites are shown in black, 
enzymes in grey. Glucose is transported to cells by glucose transporters (GLUT). 
Pyruvate is the end product of glycolysis and can be converted either to acetyl- CoA 
or lactate via lactate dehydrogenase. In hypoxia several glycolytic enzymes are up-
regulated, represented by the red arrows (22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Simplified scheme of tricarboxylic citric acid cycle (TCA). Metabolites 
are shown in black, enzymes in grey. In hypoxia, PDH is inhibited and the reductive 
glutamine metabolism is enhanced (22). 
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Enhanced glycolysis and lactate production in cancer and highly proliferating cells imply an 
increased conversion of phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP by 
pyruvate kinase (PK) (Figure 1.4). Recent studies revealed that HIF-1α activates the 
transcription of the alternative splicing variant pyruvate kinase isomer M2 (PKM2). Yang and 
co-workers identified PKM2 as a protein kinase critical for the Warburg effect and 
tumorigenesis. Monomeric PKM2 translocates to the nucleus where it functions as a protein 
kinase that phosphorylates histone H3. Consequently PKM2 activates the transcription of 
CCND1 (encoding for cyclin D1) and MYC (23). Cyclin D1 mediates cell cycle progression 
and c-Myc in turn, up-regulates the expression of the glycolytic enzymes GLUT1 and LDHA, 
increasing glucose uptake and lactate production respectively (23). Furthermore PKM2 
functions as a transcriptional coactivator of HIF-1α thereby activating the transcription of 
numerous target genes, including GLUT1, LDHA and PDK1 (23–25). Recently, PKM2 has 
also been shown to promote the Warburg effect in lipopolysaccharide-induced macrophages 
(25). 
 
1.1.6 Cellular metabolism: connecting inflammation and carcinogenesis? 
Hypoxic and inflammatory conditions have been associated with carcinogenesis (26,27) and 
associated with high glycolytic rates (10,26). Regardless of the oxygen supply many cancer 
cells shift their metabolism towards a hypoxia-like metabolic phenotype including increased 
glucose uptake, glycolytic flux, lactate production, and decreased O2 consumption. This 
phenomenon is known as the Warburg effect (20). It is assumed that this metabolic 
adaptation enables cancer cells to synthesize essential macromolecules (e.g., nucleotides, 
amino acids, and lipids) required for survival, rapid proliferation, and growth. For example, 
high glucose turnover provides necessary intermediates such as ribose-5-phosphate, serine 
and glycine for amino acid and nucleotide synthesis (20). OSM-mediated HIF-1α up-
regulation provides a link between metabolic adaptations to low oxygen tension and cancer 
cell metabolism. Therefore, OSM-induced HIF-1α up-regulation might connect chronic 
inflammation and malignant cellular transformation. IL-6-type cytokine induced STAT3 
signalling plays an important role in the regulation of many processes involved in immune 
response of tumour cells, angiogenesis, and hematopoiesis. These processes are often 
linked to an hypoxic environment with HIF-1α as important regulator. Thereby HIF-1α 
regulates the expression of many genes involved in angiogenesis, hematopoiesis and central 
carbon metabolism. However, it is still debated whether the metabolic changes are a 
consequence or a cause of carcinogenesis (28).  
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1.2 Technical background 
1.2.1 Metabolomics 
Metabolomics is the study of global metabolite profiles in a biological system at a given time 
under a defined set of conditions. It investigates intracellular and extracellular metabolites in 
biological samples, including cells grown in culture, tissue, or biological fluids (e.g. plasma, 
urine, cerebrospinal fluid). Compared to the other three big “omics”; genomics, proteomics, 
and transcriptomics, metabolomics offers unique advantages. For example, gene expression 
does not necessarily correlate with protein levels and protein activity might be regulated on a 
posttranscriptional level. Metabolites, however, reflect the end point of all those regulatory 
processes and, therefore, provide a much closer functional link to an observed phenotype.  
However, the metabolome is much more chemically diverse as for example the genome or 
proteome, which makes the metabolome analysis and interpretation of metabolome data 
challenging. To aid interpretation, metabolome analysis should, therefore, be combined with 
e.g, molecular biology techniques such as Western blot assay or real-time polymerase chain 
reaction (qPCR).  
Generally a metabolomics experiments can be divided into three main steps: sample 
preparation, analytical mass spectrometric measurements and computational data analysis 
(29–31). 
 
1.2.2 Sample preparation 
As the turnover rate of metabolites lies in the range of seconds, sample preparation requires 
an efficient quenching and metabolite extraction procedure. Quenching methods use low 
temperature and organic solvents to denature the tertiary structure of proteins and prevent 
active metabolic enzymes to change in the metabolic state. The protocols, developed for 
quenching and extraction of metabolites depend on the type of biological sample, the 
targeted metabolites (e.g. non-polar or polar metabolites) and the analytical technique 
(32,33). In this thesis, I used ice-cold methanol-water-chloroform extraction method resulting 
in the separation of three component phases: the upper polar methanol-water phase 
containing polar metabolites, the lower non-polar chloroform phase containing non-polar 
metabolites and the interphase containing total RNA, DNA and proteins. 
 
 
 
 
 
 10 
1.2.3 Gas chromatography coupled to mass spectrometry (GC-MS)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 GC-MS scheme. The samples are injected into the sample inlet and are 
separated by gas chromatography. Through the interface the separated compounds 
are processed in the mass spectrometer and their mass to charge ratio is detected. 
The mass spectrometer is composed of three blocks: an ion source, a quadrupole 
mass analyser, and a mass detector.  
 
Metabolite levels can be assessed by mass spectrometry coupled to a chromatographic 
separation technique such as gas chromatography. The GC-MS is composed of a GC and a 
MS building block (Figure 1.6). The first building block separates metabolites from a complex 
mixture by GC. Since the GC operates in a gas phase, only volatile compounds can be 
separated37. For that reason, polar carbonyl, carboxyl, and amine groups must chemically be 
modified prior to analysis. Methoxyamine hydrochloride is used to mask the carbonyl groups. 
In addition, N-Methyl-N-(trimethylsilyl)-trifluoracetamide (MSTFA) or N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) mask the carboxyl, hydroxyl, 
amine, and amide groups (Figure 1.7). The resulting chemical derivatives, trimethylsilyl 
(TMS) derivatives or tert-butyldimethylsilyl (TBDMS) are less polar, more volatile and more 
stable at high temperature than their precursors (34).  
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Figure 1.7 Chemical derivatization for GC-MS measurement. Hydrogen atoms of 
polar groups are derivatized by MSTFA and MTBSTFA, shown in blue. Carbonyl 
groups are derivatized by methoxyamine hydrochloride (MOX), shown in orange. The 
resulting TMS or TBDMS derivatives are more volatile and more stable at high 
temperature than their precursors. 
 
After the compounds are separated in the GC, they are ionized in the mass spectrometer. 
The most common ionization method used in GC-MS is electron impact ionization (EI), 
because EI ionization creates reproducible fragmentation patterns. Subsequently to 
ionization, the mass detector detects the mass to charge ratio (m/z) of these fragment ions. 
The resulting mass spectrum consists of numerous different fragment ions, also called 
isotope clusters (Figure 1.8) (35). Each isotope cluster is composed of multiple peaks 
because of naturally occurring stable isotopes (e.g. 12C and 13C for carbon or 16O and 18O for 
oxygen). A two-carbon compound creates mass spectra with three peaks, where the first 
major peak generally represents the monoisotopoic peak M+0. The low abundance peaks 
represent all combinations of the naturally abundant isotopes, usually corresponding to the 
compound with one mass unit above the monoisotopic peak M+1 (one 12C atom is replaced 
by 13C) or two mass unit above the monoisotopic peak M+2, if both 12C atoms are substituted 
by 13C. Each peak of the isotope cluster corresponds to the identical structural compound but 
different isotopic composition.  
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Figure 1.8 GC-MS mass spectrum. Typically a mass spectrum is composed of 
different fragment ions. Each fragment ion is associated to an isotope cluster. The 
monoisotopoic peak denoted as M+0 results from the combination of the lightest 
isotopes of all elements (e.g. 12C, 1H, 16O). The other peaks represent combinations of 
the naturally abundant isotopes, e.g. compounds with one mass unit above the 
monoisotopic peak are denoted M+1 and compounds with two mass units above the 
monoisotopic peak as M+2. 
 
1.2.4 Stable isotope assisted metabolomics 
Metabolomics provides the means to analyse metabolite levels and to detect changes 
thereof in response to different external perturbations. This might be sufficient to detect 
biomarkers, but in certain cases fails to detect intracellular flux changes. For example the 
abundance of citrate in the TCA cycle can be assessed for a given set of conditions. 
However, the level of citrate does not allow discerning between the PC pathway and PDH 
(Figure 1.9). In this example, pyruvate can be metabolized either to acetyl-CoA and 
eventually to citrate by PDH, or to oxaloacetate through PC, which is then converted to 
citrate.  
 
 
  
 
 
 
Figure 1.9 Simplified scheme of the tricarboxylic citric acid cycle. Either 
Pyruvate is carboxylated into oxaloacetate via PC or metabolized into acetyl-CoA by 
PDH. Acetyl-CoA enters the TCA cycle and is oxidatively decarboxylated to citrate. 
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To obtain information about intracellular fluxes, stable isotope assisted metabolomics can be 
applied. For that stable isotope labelled compounds are added to the cell culture. Beside 
deuterium (2H) and nitrogen (15N), carbon (13C) labelled compounds are used for stable 
isotope assisted metabolomics experiments. To profile central carbon metabolism, [U-
13C6]glucose or [U-13C5]glutamine are most commonly applied. Based on the enzyme 
activities within a cell, the isotopically labelled compounds are distributed within the 
metabolic network, affecting the molecular weight of pathway intermediates. These mass 
differences can be detected with GC-MS. Figure 1.10 depicts an example how stable 
isotopes can be used to differentiate between PC and PDH activity using uniformly labelled 
pyruvate as a tracer ([U-13C3]pyruvate). Depending on the respective pathway activity, 
carbon bonds of pyruvate are broken and rearranged specifically. If pyruvate is metabolized 
via PDH, two carbon atoms of citrate are pyruvate derived, leading to [13C2]citrate, whereas 
three carbons are pyruvate-derived when pyruvate is carboxylated by PC, leading to 
[13C3]citrate (36,37). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Simplified scheme of the TCA cycle. The carbon backbones of every 
metabolite are shown in circles. The black circles represent the 13C and can be used 
as indicator for the flux via PDH, while the blue circles represent 13C derived from 
carboxylation via PC. [13C2]citrate is produced through PDH and [13C3]citrate is 
produced from [13C3]oxaloacetate and unlabelled acetyl-CoA through PC.  
 
1.2.5 Mass isotopomer distribution (MID) 
Isotopic enrichment is usually quantified in form of MIDs, which describe the fractional 
abundance of each mass isotopomer of a particular compound. Mass isotopomers have the 
same structure but differ in the isotopic composition (Figure 1.11). More formally, mass 
isotopomers are groups of isotopologues of the same nominal mass (36). For example, 
pyruvate has four different mass isotopomers referred to as M0, M1, M2, and M3; unlabelled 
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pyruvate (M0), [13C1]pyruvate (M1), [13C2]pyruvate (M2), and uniformly labelled [13C3]pyruvate 
(M3).  
Based on a mass spectrometric measurement, MIDs can be determined by solving the linear 
equation system 𝐴 ∙ 𝑓 = 𝐼, where A is the correction matrix to correct for natural occurring 
isotopes, f is the vector of the fractional abundances of each mass isotopomer and I is the 
vector of the measured mass spectral intensities (32) (Figure 1.11). In the example of a two-
carbon compound (Figure 1.11), the first column of A contains the natural mass isotopomer 
distribution of the unlabelled compound (M00, M01 and M02). The second and third columns 
represent the natural mass isotopomer distribution if one of the carbon atoms is replaced by 
a 13C (M10, M11 and M12) or both carbon atoms are replaced with a 13C (M20, M21 and M22), 
respectively (Figure 1.12).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Mass isotopomer distribution of a two-carbon compound. Based on 
the number and position of incorporated labelled atoms, different isotopomers are 
shown (12C in black, 13C in red). The mass spectrum is depicted along with the 
corresponding mass isotopomer (figure based on Karsten Hiller et al., 2012). 
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Figure 1.6: Mass isotopomer distribution (MID). (a) Based on the number and posi-
tion of incorporated labeled atoms, di↵erent isotopomers are shown (12C in black, 13C
in red). The mass spectrum is depicted along with the corresponding mass isotopomer.
(b) In reality only one mass spectrum is measured for a complex mixture of mass iso-
topomers and the fraction of each mass isotopomer has to be determined by solving the
linear equation system. In this case 50% of the molecules are unlabeled, 25% contain
one stable isotope and 25% contain two stable isotopes (Figure based on [Hiller et al.,
2011])
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Figure 1.12 Mass isotopomer distribution and correction matrix. The mass 
spectrum is measured for a complex mixture of mass isotopomers and the fraction of 
each mass isotopomer (f) is determined by solving the linear equation system. In this 
case 50% of the molecules are unlabelled, 25% contain one stable isotope and 25% 
contain two stable isotopes (figure based on Karsten Hiller et al., 2012). 
 
MIDs provide the means to reveal intracellular flux changes. The importance of MIDs can be 
best explained with a short example (Figure 1.13A): using the same example as in Figure 
1.10 the MID of citrate provides direct information about the metabolic flux of pyruvate 
through PC and PDH using [13C3]pyruvate as a tracer. From the M2 and M3 mass 
isotopomers of citrate, the activity of the two pathways can be distinguished. If PDH is active, 
acetyl-CoA contains two 13C atoms and in consequence M2 citrate is produced. In contrast, 
M3 citrate is produced when pyruvate is carboxylated via PC to [13C3]oxaloacetate (Figure 
1.13B). The ratio of M2 to M3 citrate then provides information about relative activity of PDH 
to PC. 
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Figure 1.6: Mass isotopomer distribution (MID). (a) Based on the number and posi-
tion of incorporated labeled atoms, di↵erent isotopomers are shown (12C in black, 13C
in red). The mass spectrum is depicted along with the corresponding mass isotopomer.
(b) In reality only one mass spectrum is measured for a complex mixture of mass iso-
topomers and the fraction of each mass isotopomer has to be determined by solving the
linear equation system. In this case 50% of the molecules are unlabeled, 25% contain
one stable isotope and 25% contain two stable isotopes (Figure based on [Hiller et al.,
2011])
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Figure 1.13 Mass isotopomer distribution of citrate. (A) Simplified scheme of 
pyruvate dehydrogenase and pyruvate carboxylase pathway. The carbon backbones 
of every metabolite are shown in circles. The black circles represent 13C, while the 
white circles represent 12C. Using uniformly labelled pyruvate as a tracer, PDH activity 
generates acetyl-CoA containing two 13C atoms and produces M2 citrate, whereas PC 
activity generates M3 citrate via [13C3]oxaloacetate. (B) The relative isotope 
abundance of each mass isotopomer (M0, M1, M2, M3, M4, M5 and M6) of citrate is 
shown. Most of the citrate contains two 13C atoms (0.55% M2), suggesting that 
pyruvate is metabolized mostly via PDH pathway. 
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1.3 Aim of thesis 
Based on the previous finding that HIF-1α mRNA and HIF-1α protein levels are significantly 
increased in response to OSM mediated STAT3 signalling under normoxic conditions 
(Vollmer et al., 2009) (8), the purpose of this master’s thesis was to investigate the effects of 
OSM-induced HIF-1α up-regulation on central carbon metabolism in the immortalized 
hepatocyte cell line PH5CH8. OSM mediated HIF-1α up-regulation provides a common link 
between the metabolic adaptations to low oxygen tension and cancer cell metabolism, and 
therefore, might provide a causal link between chronic inflammation and malignant cellular 
transformation. For that reason, I investigated whether OSM-dependent HIF-1α up-regulation 
at normal oxygen tension results in a hypoxia like metabolic phenotype in immortalized 
hepatocytes and whether this provides a link between inflammation and malignant cellular 
transformation. To highlight the role of HIF-1α, I studied the effect of OSM stimulation and 
HIF-1α silencing in normoxic (21% O2) and hypoxic conditions (1% O2) respectively using 
stable isotope assisted metabolomics and molecular biology techniques.  
 
In this thesis, I will demonstrate that OSM treatment under normoxic conditions induces 
profound changes in cellular metabolism of PH5CH8 cells. I will show that (1) OSM 
suppresses glucose and glutamine oxidation via PDH inhibition, (2) demonstrate that OSM 
enhances reductive glutamine metabolism, (3) HIF-1α is critical for these OSM-induced 
metabolic changes.  
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2 Materials and Methods 
The following chapter describes the materials and methods for cell culture, metabolite 
extraction, molecular biology techniques and instrumental analytics. 
2.1 Experimental design 
The immortalized human PH5CH8 hepatocytes were cultivated under normoxic (21% O2, 5% 
CO2, 37°C) and hypoxic conditions (1% O2, 5% CO2, 37°C) in either [U-13C6]glucose, [U-
13C5]glutamine labelled medium or unlabelled medium. The metabolites were analysed under 
four different conditions: in the first two conditions, PH5CH8 cells were transfected with non-
targeting siRNA (siCtrl) and stimulated for 36 hours either with 50ng/mL OSM (+OSM) or 
DPBS (Figure 2.1). In the last two conditions, PH5CH8 were transfected with HIF-1α 
targeting siRNA (siHIF-1α) and stimulated either with 50ng/mL OSM or DPBS for 36 hours. 
For each condition, PH5CH8 cells were cultivated in triplicates (Figure 2.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Overview of the experimental setup. PH5CH8 were cultured in 12-well 
plates and transfected with non-targeting siRNA (siCtrl) or siRNA targeting HIF-1α 
(siHIF-1α). OSM and [U-13C6]glucose, [U-13C5]glutamine or unlabelled media were 
added to the appropriate plate. The metabolites were extracted after 36 hours and the 
samples were measured with GC-MS. Expression levels of HIF-1α, PDK1 and PKM2 
were assessed using qPCR and protein levels of HIF-1α, p-STAT3 and STAT3 were 
assessed using Western blot. 
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2.2 Cell culture conditions and growth curve 
2.2.1 Cell culture conditions 
Immortalized human hepatocytes PH5CH8 were maintained in Dulbecco Modified Eagle 
Medium (Sigma-Aldrich, DMEM 5796; 4.5 g/L glucose, L-glutamine, NaHCO3 and pyridoxine 
HCl) supplemented with 10% heat-inactivated foetal bovine serum (PAA clone, FBS with low 
endotoxine). Maintenance of PH5CH8 cells: 1:2 split each second day in T75 flasks (Thermo 
Scientific). Cells were washed once with 1x Dulbecco’s Phosphate Buffered Saline (DPBS) 
(Invitrogen) and were dispersed with trypsin EDTA (gibco by Life Technologies) for 5 min at 
37°C. The cells were grown at 37 °C, 5% CO2 and humidified atmosphere. 
2.2.2 Growth curve 
PH5CH8 cells were seeded at a density of 1.9x105 cells/well on a 6-well plate (Delta surface 
plates, Thermo Scientific) and incubated under normoxic (21% O2, 5% CO2, 37°C and 
humidified atmosphere) conditions. After 6 hours, the cells were treated either with 50 ng/mL 
OSM or left untreated. The cells were counted at four time points; 0h, 24h, 48h and 72 hours 
using the cell viability analyzer “Vi-CellTM XR” (Beckman Coulter).  
 
2.3 HIF1α silencing by reverse transfection  
For each sample, siRNA-LipofectamineTM RNAiMAX (Invitrogen) complexes were prepared 
as follows: 3 µL of LipofectamineTM RNAiMAX were diluted in 150 µL Opti-MEM I (1x) (Gibco 
by Life Technologies) and 1 µL siRNA (nontargeting siRNA Santa Cruz Biotechnology, INC.)  
or 1µL siHIF-1α (20 µM stock concentration, HIF-1α siRNA (h): sc-35561 Santa Cruz 
Biotechnology, INC.) was diluted in 150 µL Opti-MEM I (final concentration of the 
nontargeting siRNA and siHIF-1α was 15 nM). Lipofectamine and siRNA were mixed and 
incubated for 20 minutes at room temperature. 300 µL of Lipofecatmine/siRNA mix were 
transferred into a 12-well plate and incubated for 5 minutes at room temperature. PH5CH8 
cells were then seeded at a density of 7.6x104 cells/well in triplicates directly onto 
transfection mix and incubated 6 hours at 37 °C, 5% CO2 and humidified atmosphere. The 
medium was exchanged to normal culture media and the cells were incubated overnight at 
37 °C, 5% CO2 and humidified atmosphere. 
 
2.4 Preparation of labelling medium and OSM stimulation 
For isotopic labelling assisted experiments, PH5CH8 cells were cultured in DMEM 5030 
(Sigma-Aldrich, without L-glutamine, glucose, sodium pyruvate and sodium bicarbonate) 
supplemented with 10% dFBS (dialyzed fetal bovine serum, Invitrogene), 25   mM glucose 
(Aldrich chemistry) or 25 mM [U-13C6]glucose (Cambridge Isotope Laboratories, INC.) and 4 
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  mM glutamine (Sigma Life Science) or 4 mM [U-13C5]glutamine (Cambridge Isotope 
Laboratories, INC.), pH 7.4.  
 
Cells were seeded at a density of 7.6x104 cells/well and were incubated overnight at 37 °C, 
5% CO2 and humidified atmosphere. Old cell culture medium was removed and cells were 
washed with DPBS. After adding 975 µL of labelled/unlabelled media to the wells, the cells 
were stimulated either with 25 µL OSM (PEPROTECH), final concentration 50ng/mL, or with 
25 µL DPBS for untreated controls. The cells were stimulated for 36 hours at 37 °C, 5% CO2 
and humidified atmosphere under 21% or 1% O2 (Hypoxia chamber Jacomex). 
 
2.5 Intracellular and extracellular metabolite extraction 
The cell culture medium was removed from the cells, centrifuged for 5 min at maximum 
speed at 4 °C and the supernatant stored at -80 °C. For intracellular metabolite extraction 
cells were washed with 1 mL 0.9% NaCl (Sigma Life Science) and quenched with 200 µL ice-
cold methanol (Sigma Life Science, Chromasolv, pure grade for HPLC ≥ 99.9%). After 
adding 200 µL of 4 °C cold water, the cells were detached with a cell scraper (Falcon) and 
transferred to Eppendorf tubes containing 200 µL ice-cold chloroform (Sigma Life Science, 
Chromasolv pure grade for HPLC ≥ 99.9%). The extracts were mixed using a Thermomixer 
(Eppendorf) at 4 °C, 1400 rpm for 20 min and centrifuged at maximum speed for 5 min at 4 
°C. 250 µL of the upper polar phase was transferred GC-MS glass vials (Chromatographie 
Zuberhör Trott CZT) and evaporated under vacuum to dryness at −4 °C using the CentriVap 
Concentrator (Labconco). The interphase and the non-polar phase were stored at -80°C. 
Intracellular metabolite extraction of cells incubated at 1% O2 was performed in the hypoxia 
chamber. 
 
Extracellular metabolites from medium samples were extracted using ice-cold extraction fluid 
(8:1 methanol/water) containing the internal standard [U-13C5]ribitol (Omicron Biochemicals, 
INC.) at a concentration of 10 µg/mL. 20 µL of medium was added to 180 µL ice-cold 
extraction fluid, vortexed for 10 seconds and centrifuged at maximum speed for 5 min at 4 
°C. 50 µL of medium extracts were transferred to GC-MS glass vials and evaporated under 
vacuum to dryness at −4 °C using the CentriVap Concentrator. In addition an external 
calibration curve with known glucose and lactate concentration (both starting concentration 
27.5 mM, Sigma Life Science) was prepared in serial dilution of five 1:2 dilutions in H2O and 
extracted using the extraction fluid (8:1 methanol/water + [U-13C5]ribitol).  
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2.6 Metabolite derivatization 
Derivatization was carried out as previously described (André Wegner et al., 2014) (38). 
Briefly, the derivatization of intra- and extracellular metabolites was performed using a 
multipurpose sampler (Gerstel). The dried intracellular metabolite extracts were derivatized 
with N-tert- MTBSTFA. For TBDMS derivatization, dried extracts were dissolved in 15 µl 
pyridine, containing 20 mg/ml methoxyamine hydrochloride (MOX), at 55 °C for 60 min under 
shaking. After additional 15 µl MTBSTFA with 1% tert-Butyldimethylchlorosilane samples 
were incubated at 55 °C for 60 min under continuous shaking. The dried extracellular 
metabolite extracts were derivatized with MSTFA. For TMS derivatization, the extracts were 
dissolved in 15 µl pyridine, containing 20 mg/ml MOX and incubated for 60 min at 40 °C 
under shaking. Then, 15 µl MSTFA was added and the samples were incubated at 40 °C for 
30 min under continuous shaking. The chemicals for metabolite derivatisation were all 
obtained from Sigma-Aldrich. 
 
2.7 Gas chromatography-mass spectrometry (GC-MS) analysis 
GC-MS measurement was carried out as previously described (André Wegner et al., 2014) 
(38). For each condition, three replicates were measured by GC-MS using the Agilent 7890A 
GC system connected to Agilent 5975C inert XL MSD quadrupole mass spectrometer under 
electron impact (EI) ionization. 1 µL of the samples were injected into a Split/Splitless inlet 
operating in split mode (split ratio 3:1; MOX/TMS derivatization) or splitless mode 
(MOX/TBDMS derivatization) at 270 °C. Helium was used as carrier gas with a constant flow 
rate of 1 ml/min. The GC was equipped with a 30 m x 0.25 mm I.D. x 0.25 µm film thickness 
DB-35MS capillary column + 5 m DuraGuard capillary in front of the analytical column.  
For MOX/TBDMS derivatized intracellular samples, the GC oven temperature was held at 
100 °C for 3 min and increased to 300 °C at 3.5 °C/min.  
For MOX/TMS derivatized extracellular samples, the temperature was held at 80 °C for 6 min 
and increased to 300 °C at 6 °C/min.  
After 10 min, the temperature was increased at 10 °C/min followed by an additional constant 
temperature period at 325 °C for 4 min. The mass selective detector (MSD) was operating 
under electron ionization at 70 eV. The MS source was held at 230 °C and the quadrupole at 
150 °C. Full scan mass spectra were acquired from m/z 70 to 800. The total run time for 
MOX/TMS derivatized samples was 59.167 min and 60.143 min for MOX/TBDMS derivatized 
samples. The mass detector operated in single ion monitoring mode (SIM). 
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2.8 Mass isotopomer distribution analysis 
The data was processed using the MetaboliteDetector software package (Hiller et al., 2009) 
(39). The detected peaks were identified by comparing the chromatogram and the retention 
time to the reference compound library. The compound detection was performed with the 
following deconvolution settings: peak thresholds 5, minimal peak height 5, bins 10, 
deconvolution width 5. All intracellular metabolites were identified as TBDMS derivatives 
(Table 2.1). Mass isotopomer distributions were determined and corrected for natural isotope 
abundance using MetaboliteDetector.  
Weighted carbon contribution corresponds to !! M!!!! i  * i, where i is the number of stable 
isotopes in the isotopologue and M its relative isotopologue abundance using [U-13C6]glucose 
or [U-13C5]glutamine tracer.  
 
Table 2.1 GC-MS metabolites and fragments used for isotope quantification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
All extracellular metabolites were identified as TMS derivatives (Table 2.2). 
 Table 2.2 GC-MS extracellular metabolites, fragments and formula. 
 
 
 
 
 
 
 
Compound Fragment (m/z) Formula 
Alanine 2TBDMS 
260 - 268 C11H26NO2Si2 
232 - 239 C10H26NOSi2  
Aspartic acid 3TBDMS 
418 - 428 C18H40NO4Si3 
302 - 310 C14H32NO2Si2 
Citric acid 4TBDMS 591 - 602 C26H54O7Si4 
Fumaric acid 2TBDMS 287 - 297 C12H23O4Si2 
Glutamine 3TBDMS 431 - 441 C19H43N2O3Si3 
Glutamic acid 3TBDMS 
432 - 442 C19H42NO4Si3 
330 - 340 C16H36NO2Si2 
Malic acid 3TBDMS 419 - 428 C18H39O5Si3 
Lactic acid 2TBDMS 261 - 269 C11H25O3Si2 
Compound Fragments (m/z) 
Lactic acid 2TMS 117.1 191.1 219.1 
Valine 2TMS 218.1 144.1 246.1 
Leucine 2TMS 158.1 218.1 260.1 
Isoleucine 2TMS 158.1 218.1 260.1 
[U13C5]Ribitol 5TMS 207.1 220.1 323.2 
Glucose 1MeOX 5TMS 205.1 217.1 319.2 
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2.9 Quantitative real-time PCR 
The interphases were washed with 300 µL methanol, centrifuged at maximum speed at 4°C 
for 5 min and the pellets were dried under the chemical hood. Total RNA was extracted from 
the interphases using the RNA Purification kit RNeasyR Minikit (QIAGEN) following 
manufacture’s instruction. RNA concentration was measured using the NanoDrop (Thermo 
Scientific). cDNA was prepared using 1 µL of oligonucleotide (oligo DT 50 µM, Invitrogen), 
600 ng total RNA and 1 µL dNTP (deoxyribonucleotide triphosphate 10mM, Sigma Life 
Science) mix and RNase free water (Sigma Life Science) up to 13 µL. The samples were 
denatured at 65 °C for 5 minutes and incubated on ice for 1 minute. Reverse transcription 
was performed using 4 µL 5x First-Strand buffer (250 mM Tris-HCl (pH 8.3 at room 
temperature), 375 mM KCl, 15 mM MgCl2), 1 µL 0.1 M DTT (Invitrogen), 1 µL RNaseOUTTM 
Recombinant RNase Inhibitor (Invitrogen) and 1 µL SuperScriptTM III RT (Invitrogen) for 60 
minutes at 50°C and inactivated at 70°C for 15 minutes. The cDNA concentration was 
measured using NanoDrop. cDNA (amount of cDNA used for qPCR: 600 ng) was used as a 
template for quantitative real-time PCR analysis under the conditions in Table 2.4 using the 
LightCycler 480 detection system. The primer pairs were used for quantitative real-time PCR 
as listed in Table 2.3. For each primer, a master mix was prepared as follows: For each 
sample 0.5 µL of forward primer, 0.5 µL of reverse primer, 7 µL ddH2O and 10µL Syber 
Green (BIO-RAD). 2 µL of cDNA were used per PCR reaction. 
Table 2.3 Primer sequences for qPCR. 
Gene Symbol Sequence (5’-3’) Supplier 
Human 
HIF1α 
 
forward CGTTCCTTCGATCAGTTGTC 
reverse TCAGTGGTGGCAGTGGTAGT 
Eurogentec 
Human 
PDK1 
 
forward GCACTCTTTATTGTTTGGTGG 
reverse ACGCCTAGCATTTTCATAGC 
Eurogentec 
Human 
PKM2 
 
forward CAGAGGCTGCCATCTACCAC 
reverse CCAGACTTGGTGAGGACGAT 
Eurogentec 
Human 
PKM1 
 
forward GAGGCAGCCATGTTCCAC 
reverse TGCCAGACTCCGTCAGAACT 
Eurogentec 
Human 
L27  
(housekeeping gene) 
forward CTG GTG GCT GGA ATT GAC 
reverse ACA GAG TAC CTT GTG GGC 
Eurogentec 
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Table 2.4 qPCR conditions. 
temperature time cycles 
95°C 5 min  
95°C 
60°C 
72°C 
30 s 
30 s 
30 s 
 
45 
95°C 15 s  
40°C 1h 30 min  
 
 
 
2.10 Western Blot 
2.10.1 Protein extraction 
PH5CH8 cells were seeded at a density of 1.9x105 cells/well on a 6-well plate, transfected 
with non-targeting or HIF-1α targeting siRNA and stimulated with OSM for 36 hours under 
normoxia and hypoxia (1% O2). Proteins were extracted with 120 µL of mammalian protein 
extraction reagent (M-PER) (Thermo Scientific) supplemented with proteinase inhibitors 
(Roche) and extracts were mixed 10 min, 1.400 rpm at 4 °C using the Thermomixer. After 
centrifuging for 10 min at maximum speed and at 4 °C, the supernatant was transferred into 
an Eppendorf tube and used for SDS-PAGE. The protein concentration was measured with 
the Nanodrop.  
A positive control for HIF-1α was included. HeLa cells were stimulated with 75 µM cobalt 
chloride (Sigma Life Science), incubate at 37 °C, 5% CO2 and humidified atmosphere for 4 
hours. Proteins were extracted as described above.  
2.10.2 SDS-Page 
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-Page). Protein extracts were diluted in 5x Laemmli buffer (Trizma HCl, ß-
mercaptoethanol, glycerol, SDS, Bromophenol red, ddH2O) to load 20 µg of protein and 
denatured for 5 min at 95 °C. 15 µL of protein extract were loaded on a 10% Mini-Protean 
TGX Precast Gel (BIO-RAD). Precision Plus protein kaleidoscope standards (BIO-RAD) 
severed as marker. The gel ran 15 minutes at 90 V and 60 min at 120 V. 
2.10.3 Western Blotting 
Separated proteins were transferred to a PVDF membrane (Immobilon PVDF membranes), 
which was activated for 30 seconds in 100% MeOH (Sigma-Aldrich). The transfer was 
performed at 80V in 1x transfer buffer with 20% MeOH (10x transfer buffer: 200mM Trizma-
Base, 1.92mM Glycine, ddH2O to 1 L, from Sigma Life Science). The blot ran at 80 V for one 
hour. The PVDF membrane was blocked with 10% BSA (Albumin Fraction V (pH 7.0) blotting 
grade, from AplliChem Panreac) in 1x TBS-T with 0.1% Tween (10x TBS: 200mM Trizma-
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Base, 137 M NaCl, ddH2O to 1 L) for 1 hour at room temperature, washed three times with 
1x TBST and incubated with primary antibodies against HIF-1α (BD Bioscience, purified 
Mouse Anti-human HIF-1α) diluted 1:1000 in 5% BSA in TBS-T, phospho-STAT3 (cell 
signaling, purified rabbit anti-human) diluted 1:1000 in 5% BSA in TBS-T and ß-actin (Sigma, 
purified mouse anti-human) diluted 1:5000 in 5% milk in TBS-T. The blots were incubated 
over night at 4°C with constant shaking. The membranes were washed with 1x TBS-T and 
incubated with the secondary antibodies anti-mouse coupled to horseradish peroxidase 
(HRP) diluted 1:5000 in 5% BSA or 5% milk, depending on the first antibody, and anti-rabbit 
coupled to HRP diluted 1:5000 in 5% BSA for 1 hour at room temperature. After three 
washing steps with 1x TBS-T, the secondary antibodies were detected using Luminol ECL 
reagent (ECLTM Western blotting Detection Reagent, GE healthcare) with Odyssey 2800 
(Licor), channel 700 for 30 seconds and Chemi for 2 minutes. 
The quantification of the protein bands from the membrane was performed using ImageJ 
(Image Processing and Analysis in Java, http://imagej.nih.gov/ij) software, providing the band 
intensities. The level of HIF- 1α, STAT3 and p-STAT3 proteins were normalized to ß-actin 
protein level. Then p-STAT3 protein level was normalized to the STAT3 protein level. 
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3 Results 
The aim of this master’s thesis was to investigate the role of HIF-1α in OSM-induced 
metabolic reprogramming of human hepatocytes.  
Since HIF-1α is the master regulator of the cellular response to low oxygen levels, I 
hypothesized that OSM reprograms cellular metabolism of the immortalized human 
hepatocyte PH5CH8 cell line to a hypoxia-like metabolic phenotype and that those changes 
are mediated by HIF-1α.  
 
3.1 OSM treatment increases transcription and protein levels of HIF-1α  
Based on the previous finding that HIF-1α mRNA and protein levels are increased in 
response to OSM-mediated STAT3 signalling under normoxic conditions (Vollmer, Kappler et 
al., 2009)(8) in immortalized hepatocytes and hepatocellular carcinoma cells (HepG2), I first 
aimed to validate whether OSM increases the expression level of HIF-1α in PH5CH8 cells. 
The relative expression level of HIF-1α was significantly (Welch’s t-test; p = 0.024) increased 
upon OSM stimulation at 21% O2 (Figure 3.1). At 1% O2, HIF-1α transcription was also 
induced by OSM (Welch’s t-test; p = 0.005). However, at 1% O2 the overall HIF-1α mRNA 
level was decreased as compared to 21% O2 (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1 OSM induces HIF-1α up-regulation in human hepatocytes PH5CH8 
under normoxic and hypoxic conditions. PH5CH8 cells were treated either with 
OSM (siCtrl+OSM) or DPBS (siCtrl) in normoxia and hypoxia. The fold change was 
calculated relative to the untreated control. Error bars represent the standard 
deviation from at least two independent replicates (n≥2), Welch’s t-test; *p < 0.05, **p 
< 0.01. 
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Subsequently, I investigated whether OSM induces STAT3 phosphorylation and increases 
HIF-1α protein levels under normoxic conditions. OSM significantly induced STAT3 
phosphorylation under both normoxia (Welch’s t-test; p = 3E-05) and hypoxia (Welch’s t-test; 
p = 2E-04) (Figure 3.2A and C), whereas HIF-1α protein levels were solely increased by 
OSM under normoxia (Welch’s t-test; p = 0.008) (Figure 3.2A, B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 OSM stimulation results in an increase of HIF-1α protein levels under 
normoxia. (A) Western blot for HIF-1α, STAT3 and p-STAT3. PH5CH8 cells were 
treated either with OSM (siCtrl+OSM) or with DPBS (siCtrl) in normoxia or hypoxia. 
As positive control HeLa cells were treated with CoCl2. (B)&(C) Quantification of HIF-
1α and phospho-STAT3 protein levels in PH5CH8 cells. HIF-1α levels were 
normalized to ß-actin and p-STAT3 was normalized to STAT3. Error bars represent 
the standard deviation of at least two biological replicates), Welch’s t-test; *p < 0.05, 
**p < 0.01 and ***p < 0.001. 
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3.2 OSM supresses glucose oxidation via PDH inhibition 
Since HIF-1α is known to suppress glucose oxidation in the TCA cycle (10), I first studied the 
effect of OSM treatment on glucose oxidation in PH5CH8 cells using stable isotope assisted 
metabolomics. Therefore, I cultured PH5CH8 cells in medium supplemented with 25 mM [U-
13C6]glucose and stimulated either with OSM (siCtrl+OSM) or with DPBS (siCtrl) (Figure 2.1). 
After GC-MS measurements, I quantified the isotopic enrichment in form of MIDs for several 
TCA cycle metabolites, including citrate, α-ketoglutarate, malate, fumarate, aspartate, 
glutamate and glutamine. 
At 21% O2, I observed significantly (Welch’s t-test; p = 0.004) increased M0 citrate 
isotopologues in OSM-treated cells compared to the control (Figure 3.3A). Increased M0 
citrate isotopologues propagated to the analysed downstream metabolites of the TCA cycle 
α-ketoglutarate, fumarate, malate, glutamate and aspartate (Figure 3.4 and Supplemental 
Table 1.). M0 isotopologues represent the fraction of citrate not enriched from [U-
13C6]glucose, suggesting that upon OSM stimulation the majority of citrate is metabolized 
from an alternative carbon source. To further analyse the glucose carbon contribution to 
citrate, I quantified the weighted contribution of glucose-derived carbons to citrate (2.8 mass 
isotopomer distribution analysis). In line with the increased M0 isotopologues of citrate, I 
observed significantly (Welch’s t-test; p = 0.006) decreased glucose-derived carbon in citrate 
in response to OSM treatment (Figure 3.5).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Mass isotopomer distributions of citrate from [U-13C6]glucose in (A) 
normoxia and (B) hypoxia. Error bars represent the standard deviation from at least 
two independent replicates (n≥2). Welch’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001 
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Figure 3.4 Mass isotopomer distribution of (A) malate and (B) aspartate in 
normoxia from [U-13C6]glucose. Error bars represent the standard deviation from at 
least two independent replicates (n≥2). Welch’s t-test, *p < 0.05, **p < 0.01. 
 
 
 
 
 
 
 
 
Figure 3.5 Effect of OSM stimulation on relative glucose carbon contribution to 
citrate under normoxia and hypoxia. Weighted carbon contribution was calculated 
as described in section 2.8. Error bars represent the standard deviation from at least 
two independent replicates (n≥2), Welch’s t-test;  *p < 0.05, **p < 0.01. 
 
Glucose-derived carbons can enter the TCA cycle via two ways: either through pyruvate 
dehydrogenase (PDH) complex or through pyruvate carboxylase (PC). In order to distinguish 
both pathways and investigate whether the observed reduced glucose carbon contribution to 
citrate results from reduced PC or reduced PDH activity, I analysed the labelling pattern of 
citrate (Figure 3.6A). If PC is active, [13C3]pyruvate is carboxylated to [13C3]oxaloacetate and 
,thus , condensation of [13C3]oxaloacetate and unlabelled acetyl-CoA results in M3 citrate. In 
contrast, M2 citrate isotopologues result from [U-13C6]glucose-derived [13C3]pyruvate that is 
metabolized to [13C2]acetyl-CoA. Subsequently, [13C2]acetyl-CoA is condensed with 
unlabelled oxaloacetate to [13C2]citrate (M2 isotopologues). M4 citrate is metabolized in a 
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second round of the TCA cycle, resulting from [13C2]acetyl-CoA and [13C2]oxaloacetate via 
citrate synthase. In addition, M5 isotopologues of citrate result from [13C3]oxaloacetate and 
[13C3]pyruvate-derived [13C2]acetyl-CoA, thereby giving a readout of the combined activity of 
PDH and PC (Figure 3.6A). I observed that OSM stimulation resulted in reduced M2 and M4 
isotopologues of citrate compared to the control (A). At 21% O2, I did not observe any 
difference in M3 and M5 citrate isotopologues upon OSM stimulation (A), suggesting that the 
reduced glucose carbon contribution to citrate is caused by decreased PDH activity. To avoid 
that the observed differences are effects from the overall enrichment, I normalized the M2 
and M3 citrate isotopologues to M3 lactate isotopologues and observed significantly (Welch’s 
t-test; p = 5E-05) reduced PDH activity (Figure 3.6D), but no effect on PC activity (Figure 
3.6B) in OSM-stimulated cells under normoxic conditions compared to the control. The 
overall PC activity was relatively low under normoxic conditions (Figure 3.6B) suggesting that 
pyruvate-derived carbon almost exclusively enters the TCA cycle through acetyl-CoA and not 
through oxaloacetate.  
In response to OSM stimulation, reduced amount of M2 isotopologues propagated to 
downstream metabolites in the TCA cycle, including α-ketoglutarate, fumarate, malate, 
glutamate and aspartate (Figure 3.4 and Supplemental table 2.). These data suggest that 
reduced PDH activity is responsible for the observed reduced glucose carbon contribution to 
citrate. 
Since the PDH complex is mainly regulated post-translationally by PDK1, which 
phosphorylates the PDH E1α subunit, thereby inactivating the PDH enzyme complex(16), I 
next determined the expression level of PDK1 (Figure 3.6C). In line with decreased M2 
isotopologues of citrate, I observed significantly (Welch’s t-test; p = 0.0204) increased PDK1 
transcription in response to OSM stimulation under normoxia (Figure 3.6C). 
Altogether, this data strongly suggests that OSM treatment increases the expression of 
PDK1 under normoxia, thereby inhibiting PDH and limiting glucose oxidation in the TCA 
cycle. 
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Figure 3.6 Effect of OSM stimulation on PC and PDH activity, and PDK1 
transcription in normoxic and hypoxic conditions. (A) Carbon atom transitions of 
PC and PDH. (B) Relative PC activity, determined by the ratio of M3 isotopologues of 
citrate to M3 isotopologues of lactate, from [U-13C6]glucose. (C) qPCR of PDK1 
mRNA. (D) PDH activity determined by the ratio of M2 isotopologues of citrate to M3 
isotopologues of lactate, from [U-13C6]glucose. Error bars represent the standard 
deviation from at least two independent replicates (n≥2), Welch’s t-test; **p < 0.01 
and ***p < 0.001.  
 
In order to investigate whether the OSM-induced suppression of glucose oxidation is 
comparable to the metabolic phenotype induced by hypoxia, I analysed the MIDs of citrate 
and downstream metabolites at 1% O2. Under hypoxia, the majority of citrate was not 
enriched from [U-13C6]glucose, suggesting that most of the citrate carbon is not derived from 
glucose (Figure 3.3B). In agreement with the high amount of M0 isotopologues of citrate, I 
observed increased PDK1 transcription in PH5CH8 cells grown under hypoxia (Figure 3.5 
and 3.6B). Consequently, PDH activity was suppressed and glucose oxidation limited (Figure 
3.6D). As a result of reduced PDH activity, M2 and M4 isotopologues of citrate and 
downstream metabolites of the TCA cycle were highly decreased at 1% O2 compared to 21% 
O2 (Figure 3.3B and Supplemental Table 3.). At 1% O2, I did not observe any effect on 
glucose oxidation and PDH activity upon OSM treatment. However, I observed a slight 
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decrease in PDK1 transcription in OSM-stimulated cells under hypoxia compared to the 
control (Figure 3.6C).  
OSM-induced PDK1 up-regulation and PDH inhibition represented an intermediate state 
between cells grown under normoxia and hypoxia. The resulting changes in MID of citrate, 
including increased M0 and decreased M2 or M4 isotopologues, and the reduced glucose 
oxidation induced by OSM under normoxia were less pronounced compared to the changes 
induced by hypoxia.  
Collectively, these data show that the level of glucose oxidation and PDH activity upon OSM 
treatment under normoxia represents an intermediate metabolic phenotype between 
normoxia and hypoxia.  
 
 
3.3 Glutamine oxidation in the TCA cycle is reduced in response to OSM stimulation 
Since OSM stimulation suppresses glucose oxidation in the TCA cycle by PDH inhibition, I 
next studied whether this effect was compensated by an increased glutamine oxidation. 
Therefore, PH5CH8 cells were cultured in medium containing 4 mM [U-13C5]glutamine under 
normoxic and hypoxic conditions (Figure 2.1). OSM-treated cells exhibited significantly  
reduced M4 and M2 citrate isotopologues compared to the control under normoxia (Welch’s 
t-test; M2 p = 0.002 / M4 p = 3E-05) (Figure 3.7A). [13C4]citrate results from [U-
13C5]glutamine-derived [13C5]α-ketoglutarate that is eventually converted in the TCA cycle to 
[13C4]oxaloacetate. Subsequently, [13C4]oxaloacetate and unlabelled acetyl-CoA are 
condensed to [13C4]citrate (Figure3.8B), thereby providing a readout of relative glutamine 
oxidation in the TCA cycle. Furthermore, I observed that under normoxia reduced M2 and M4 
isotopologues propagated to the downstream metabolites fumarate, malate, and aspartate 
upon OSM stimulation (Supplemental Table 2.).  
To exclude bias from the overall enrichment, I normalized the M4 isotopologues of citrate 
with the M5 isotopologues of α-ketoglutarate. I observed a significant (Welch’s t-test; p = 5E-
07) drop in the M4 citrate to M5 α-ketoglutarate ratio (Figure 3.8A), suggesting a decrease in 
relative glutamine oxidation. 
 
At 1% O2, I observed a significant (Welch’s t-test; p = 1E-06) drop of the M4 citrate to M5 α-
ketoglutarate ratio compared to 21% O2 (Figure3.7B), pointing to suppressed glutamine 
oxidation in hypoxic conditions. There was no difference in glutamine oxidation under 
hypoxia upon OSM treatment (Figure 3.8A). 
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Figure 3.7 Mass isotopomer distributions of citrate from [U-13C5]glutamine in (A) 
normoxic and (B) hypoxic conditions. Error bars represent the standard deviation from 
at least two independent replicates (n≥2). Welch’s t-test; **p < 0.01, ***p < 0.001  
 
 
 
 
 
 
 
 
 
Figure 3.8 Effect of OSM on oxidative glutamine metabolism under normoxia 
and hypoxia. (A) Relative glutamine oxidation in the TCA cycle, determined by the 
ratio of M4 isotopologues of citrate to M5 isotopologues of α-ketoglutarate from [U-
13C5]glutamine. Error bars represent the standard deviation from at least two 
independent replicates (n≥2), Welch’s t-test; *p < 0.05, **p < 0.01. (B) Simplified 
scheme of TCA cycle with carbon atom transitions of oxidative and reductive 
glutamine metabolism.  
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3.4 OSM stimulation increases reductive glutamine metabolism 
Although glutamine oxidation was significantly (Welch’s t-test; p = 5E-07) decreased, the 
fractional contribution of glutamine-derived carbon to citrate was moderately increased in the 
OSM-treated cells compared to the control (Welch’s t-Test; p = 0.001) (Figure 3.9). These 
results indicate that in OSM-stimulated cells, citrate is derived from glutamine through an 
alternative pathway, other than the oxidative TCA cycle. Therefore, I investigated whether 
OSM stimulation would lead to increased reductive glutamine metabolism under normoxia. 
Citrate can be metabolized through reductive carboxylation of α-ketoglutarate via IDH (Figure 
3.7C), which leads to M5 isotopologues of citrate. Glutamine-derived [13C5]α-ketoglutarate 
and unlabelled CO2 are metabolized to [13C5]isocitrate via IDH, followed by isomerization of 
[13C5]isocitrate to [13C5]citrate by aconitase (Figure 3.7C). I observed that the ratio of M5 
citrate to M5 α-ketoglutarate was significantly (Welch’s t-test; p = 2E-04) increased upon 
OSM stimulation as compared to the untreated control (Figure 3.10).   
 
 
 
 
 
 
 
Figure 3.9 Effect of OSM on relative glutamine carbon contribution to citrate 
under normoxia and hypoxia. Error bars represent the standard deviation from at 
least two independent replicates (n≥2), Welch’s t-test;  *p < 0.05, **p < 0.01. 
 
 
 
 
 
 
 
 
Figure 3.10 Effect of OSM stimulation on reductive glutamine metabolism. 
Relative reductive flux, determined by the ratio of M5 isotopologues of citrate to M5 
isotopologue of α-ketoglutarate in normoxia and hypoxia from [U-13C5]glutamine. Error 
bars represent the standard deviation from at least two independent replicates (n≥2), 
Welch’s t-test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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In line with these results, M3 isotopologues of fumarate, malate and aspartate were also 
significantly increased upon OSM stimulation under normoxia (Welch’s t-test; malate p = 6E-
05 / aspartate p = 3E-04) (Figure 3.11 an Supplemental Table 2.). M3 isotopologues of 
fumarate, malate, and aspartate derive from [13C5]citrate, which is cleaved to 
[13C3]oxaloacetate and [13C2]acetyl-CoA by citrate lyase.  
 
 
 
 
 
 
 
 
 
Figure 3.11 Effect of OSM on M3 isotopologue abundances of (A) malate and (B) 
aspartate in normoxic conditions from [U-13C5]glutamine. Error bars represent the 
standard deviation from at least two independent replicates (n≥2), Welch’s t-test; *p < 
0.05, **p < 0.01 and ***p < 0.001. 
 
These results strongly suggest that under normoxia reduced glucose and glutamine oxidation 
via PDH inhibition is at least partly compensated by an increased reductive IDH flux to 
maintain the citrate pool upon OSM stimulation. 
Under hypoxic conditions, the M5 citrate to M5 α-ketoglutarate ratio was significantly 
(Welch’s t-test; p = 0.0005) increased compared to OSM-stimulated cells under normoxia 
(Figure 3.10). I did not observe any effects of OSM treatment on reductive glutamine 
metabolism under hypoxia (Figure 3.10).  
 
 
3.5 OSM increases glucose uptake and lactate secretion 
To analyse whether OSM stimulation enhances glucose uptake and lactate production, I 
measured glucose consumption and lactate secretion in PH5CH8 cells. Glucose uptake was 
slightly increased by OSM treatment (Figure 3.12A). In line with increased glucose uptake 
and reduced glucose oxidation in the TCA cycle, I observed slightly increased lactate 
secretion upon OSM stimulation under normoxic conditions (Figure 3.12B). These results 
indicate that PH5CH8 cells exhibit a more glycolytic phenotype in response to OSM 
stimulation. 
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Figure 3.12 Effect of OSM stimulation on glucose uptake and lactate secretion 
under normoxia. (A) Glucose uptake and (B) lactate secretion determined by GC-
MS. Signal intensities were normalized to cell numbers. Error bars represent the 
standard deviation from at least two independent replicates (n≥2). 
 
Since the expression of PKM2 is increased in many human cancer cells and is associated 
with increased glucose uptake and increased lactate production (23), I investigated whether 
OSM stimulation leads to increased PKM2 transcription in PH5CH8 cells. Therefore, I 
determined the mRNA levels of PKM2 in normoxic and hypoxic conditions by qPCR. I did not 
observe any difference in the expression of PKM2 between OSM-stimulated and untreated 
cells under normoxia. However under hypoxia, PKM2 mRNA levels were increased as 
compared to the cells cultured in normoxia, but remained unaffected upon OSM stimulation 
(Figure 3.13).  
 
 
 
 
 
 
 
Figure 3.13 OSM stimulation on relative PKM2 mRNA expression levels under 
hypoxia and normoxia.  
 
 
3.6 OSM stimulation does not increase the proliferation rate of PH5CH8 
Since IL-6 stimulation was shown to increase hepatocyte proliferation (40), I examined 
whether OSM stimulation contributes to increased proliferation rates of PH5CH8 cells. 
Therefor, I cultured PH5CH8 cells either with OSM or with DPBS and counted cells 24 and 
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48 hours after OSM stimulation. I observed no significant effect on cell proliferation upon 
OSM stimulation under normoxia (Figure 3.14).  
 
 
 
 
 
 
 
 
Figure 3.14 Effect of OSM treatment on PH5CH8 growth under normoxia. 
PH5CH8 cells were treated either with OSM or with DPBS. The cells were counted at 
three time points; 0, 24 and 48 hours. Error bars represent the standard deviation 
from three independent replicates. 
3.7 HIF-1α is critical for the OSM-induced metabolic changes 
To prove the importance of HIF-1 α for the OSM-induced metabolic reprogramming in 
immortalized human hepatocytes, I performed silencing experiments using non-targeting and 
HIF-1α targeting siRNA. Silencing of HIF-1α significantly decreased its transcription under 
normoxia (Welch’s t-test p = 4E-04) and hypoxia (Welch’s t-test p = 0.0044) (Figure 3.15). In 
HIF-1α-silenced cells, OSM-stimulation slightly increased transcription of HIF-1α under 
normoxia and hypoxia (Figure 3.15). 
In line with decreased transcription, silencing of HIF-1α resulted in highly reduced HIF-1α 
protein levels compared to the OSM-treated control under normoxia and hypoxia. I observed 
a minor increase in HIF-1α protein levels and increased phosphorylation of STAT3 upon 
OSM stimulation (Figure 3.16A, B and C). 
 
 
 
 
 
Figure 3.15 mRNA levels of HIF-1α relative to siCtrl under (A) normoxia and (B) 
hypoxia. Error bars correspond to the standard deviation of at least two independent 
biological replicates, Welch’s t-test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Figure 3.16 OSM stimulation results in an increase of HIF-1α protein levels 
under normoxia. (A) Western blot. PH5CH8 cells were treated either with OSM 
(siCtrl+OSM) or with DPBS (siCtrl) in normoxia or hypoxia. As positive control HeLa 
cells were treated with CoCl2. (B)&(C) HIF-1α and phospho-STAT3 protein levels are 
shown relative to siCtrl in PH5CH8 cells. Protein levels of HIF-1α were normalized to 
ß-actin protein levels and p-STAT3 levels were normalized to STAT3. Error bars 
represent the standard deviation of at least two biological replicates. Welch’s t-test, *p 
< 0.05, **p < 0.01 
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Next, I investigated whether HIF-1α activity is critical for OSM-induced suppression of 
glucose oxidation in the TCA cycle. The MIDs of citrate barely changed upon OSM 
stimulation in the HIF-1α silenced cells under normoxia (Figure 3.17A) and were comparable 
to the MIDs of the untreated control (A). The previously observed decreased glucose 
contribution to citrate upon OSM was completely impeded in the HIF-1α silenced cells 
(Figure 3.18A). Furthermore, PDH activity was not affected upon OSM-treatment in HIF-1α 
silenced cells (Figure 3.19B). In agreement with these data, OSM treatment reduced PDK1 
expression under normoxia in HIF-1α silenced cells (Figure 3.19A). 
Under hypoxia, silencing of HIF-1α led to increased glucose carbon contribution to citrate 
(Figure 3.18B) and increased PDH activity (Figure 3.19B). 
Altogether, these results strongly suggest that HIF-1α is indispensable for the OSM-mediated 
reprogramming of glucose oxidation via PDK1 up-regulation, and thus, PDH inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Effect of HIF-1α silencing on the MID of citrate from [U-13C6]glucose 
under (A) normoxia and (B) hypoxia. Error bars represent the standard deviation from 
at least two independent replicates (n≥2). 
 
 
 
 
0"0.05"
0.1"0.15"
0.2"0.25"
0.3"0.35"
0.4"0.45"
0.5"
M0" M1" M2" M3" M4" M5" M6"
!r
el
at
iv
e!
ab
un
da
nc
e!
normoxia!
Citrate!
A 
+0.1"0"
0.1"0.2"
0.3"0.4"
0.5"0.6"
0.7"0.8"
0.9"1"
M0" M1" M2" M3" M4" M5" M6"
re
la
ti
ve
!a
bu
nd
an
ce
!
hypoxia!
Citrate!
siHIF+1α""siHIF+1α+OSM"
B 
 
0"0.05"
0.1"0.15"
0.2"0.25"
0.3"0.35"
0.4"0.45"
0.5"
M0" M1" M2" M3" M4" M5" M6"
!r
el
at
iv
e!
ab
un
da
nc
e!
normoxia!
Citrate!
A 
+0.1"0"
0.1"0.2"
0.3"0.4"
0.5"0.6"
0.7"0.8"
0.9"1"
M0" M1" M2" M3" M4" M5" M6"
re
la
ti
ve
!a
bu
nd
an
ce
!
hypoxia!
Citrate!
siHIF+1α""siHIF+1α+OSM"
B 
 40 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Effect of HIF-1α silencing on relative glucose carbon contribution to 
citrate under (A) normoxia and (B) hypoxia. Error bars correspond to the standard 
deviation of at least two independent biological replicates, Welch’s t-test; *p < 0.05, 
**p< 0.01 and ***p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Effect of HIF-1α silencing on relative PDK1 transcription and PDH 
activity under normoxia and hypoxia. (A)  PDK1 mRNA levels under hypoxia and 
normoxia. The fold change was calculated relative to the untreated control. (B) PDH 
activity determined by the ratio of M2 isotopologues of citrate to M3 isotopologues of 
lactate, from [U-13C6]glucose. The ratio was calculated relative to the untreated 
control. Error bars represent the standard deviation from at least two independent 
replicates (n≥2), Welch’s t-test; *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Next, I investigated the effect of HIF-1α silencing on glutamine metabolism. Similarly to the 
glucose tracer, citrate MIDs from [U-13C5]glutamine were not affected by OSM in HIF-1α 
silenced cells (Figure 3.20A). Silencing of HIF-1α almost completely prevented the OSM-
induced changes in glutamine metabolism. Specifically, glutamine oxidation in the TCA cycle 
was only slightly decreased upon OSM stimulation in HIF-1α silenced cells and comparable 
to the untreated control (Figure 3.21A). Moreover, reductive carboxylation of α-ketoglutarate 
was only slightly induced by OSM treatment in HIF-1α silenced cells (Figure 3.22A). In line 
with these data, the glutamine carbon contribution to citrate was not affected by OSM 
treatment (Figure 3.22B).  
Collectively, these data show that silencing of HIF-1α almost completely prevented the 
metabolic reprogramming induced by OSM stimulation, including suppression of glucose and 
glutamine oxidation via PDH inhibition, reduction of glucose and increase of glutamine 
carbon contribution to citrate, as well as the increase in reductive glutamine metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Effect of HIF-1α silencing on the MID of citrate from [U-
13C5]glutamine under (A) normoxia and (B) hypoxia. Error bars represent the 
standard deviation from at least two independent replicates (n≥2).  
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Figure 3.21 Metabolic effect of HIF-1α silencing on oxidative glutamine 
metabolism under (A) normoxia and (B) hypoxia. Error bars represent the standard 
deviation from at least two independent replicates (n≥2), Welch’s t-test; *p < 0.05, **p 
< 0.01 and ***p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.22 Effect of HIF-1α silencing on reductive glutamine metabolism and 
relative glutamine carbon contribution to citrate in normoxia and hypoxia from 
[U-13C5]glutamine. (A) Relative reductive glutamine metabolism, determined by the 
ratio of M5 isotopologues of citrate to M5 isotopologues of α-ketoglutarate. (B) 
Glutamine carbon contribution to citrate was calculated relative to untreated control 
cells. Error bars correspond to the standard deviation of at least two independent 
biological replicates, Welch’s t-test; *p < 0.05, **p < 0.01. 
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In line with the results under normoxia, silencing HIF-1α reduced the metabolic 
reprogramming induced by hypoxia. Specifically, HIF-1α silencing led to an up-regulation of 
glucose and glutamine oxidation (Figure 3.21B). Moreover, silencing of HIF-1α increased 
PDH activity via PDK1 suppression, glucose carbon contribution to the TCA cycle (Figure 
3.18, Figure 3.19), and decreased reductive carboxylation (Figure 3.22A). Glutamine carbon 
contribution to citrate decreased in HIF-1α silenced cells in under hypoxia (Figure 3.22B). 
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4 Discussion 
 
Most tumours, which are composed of highly proliferating cells, rely on aerobic glycolysis, a 
phenomenon known as Warburg effect (20). Regardless the oxygen supply, these cells 
adapt their cellular metabolism towards a more glycolytic metabolic phenotype, by altering 
gene expression of crucial metabolic enzymes, which results in increased glucose uptake, 
high glycolytic flux, and increased lactate secretion.  
Under hypoxic conditions, alterations in central carbon metabolism are mainly mediated by 
the transcription factor HIF-1α, a key regulator of the cellular response to hypoxia (10). 
Hypoxia and inflammation are often interdependent and both microenvironments have been 
associated with carcinogenesis (26,27). Many cancers are suggested to be preceded by 
chronic inflammation, indicating that inflammatory responses play a critical role at different 
stages of cancer development, including initiation, invasion, and metastasis (27). In 
particular, most hepatocellular carcinomas are preceded by chronic inflammation due to viral 
hepatitis infections (hepatitis B and C virus), suggesting that an inflammatory 
microenvironment promotes HCC development (1). IL-6-type cytokines are key regulators of 
this immune response, and play an important role in chronic inflammation and in the 
regulation of cancer development (2). Previous studies (41,42) showed that IL-6 signalling is 
implicated in the onset of HCC in response to chronic hepatitis B, and both liver injury and 
proliferation are strongly dependent on IL-6 in a mouse model (5,41,42). 
 
In this study, I investigated the role of HIF-1α in metabolic reprogramming of human 
hepatocytes induced by the inflammatory cytokine OSM. Recently, it was shown that in 
immortalized hepatocytes and HCC cells the IL-6-type cytokine OSM up-regulates HIF-1α 
expression under normoxic conditions (8). Vollmer and colleagues showed that in response 
to the OSM-induced JAK/STAT3 signalling cascade, HIF-1α mRNA and HIF-1α protein levels 
are increased under normoxic conditions (21% O2) (8). Furthermore, it was shown that 
STAT3 is required to increase HIF-1α mRNA levels in both mouse cells and human 
melanoma cell line (43). In line with these studies, I demonstrated that in the immortalized 
human hepatocyte cell line PH5CH8, HIF-1α transcription and protein levels are up-regulated 
in response to OSM. HIF-1α up-regulation is mediated by OSM induced activation of 
JAK/STAT3 signalling, where STAT3 directly acts as a transcriptional regulator of HIF-1α (8).  
Under hypoxia, HIF-1α transcription was enhanced upon OSM treatment, and the overall 
HIF-1α protein levels were increased. However, at 1% O2 the overall HIF-1α mRNA levels 
were decreased as compared to normoxia. Uchida and colleagues showed that prolonged (> 
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12 hours) or acute (< 0.5 % O2) hypoxia in the human lung adenocarcinoma cell line A549 
and in human lung microvascular endothelial cells result in reduced HIF-1α mRNA levels 
(44). Thereby, HIF-1α proteins negatively regulate HIF-1α mRNA through an increase in 
natural antisense HIF-1α (44). In line with these findings, I observed decreased HIF-1α 
mRNA levels after 36 hours of hypoxia compared to normoxia.  
OSM stimulation did not enhance HIF-1α protein levels under hypoxic conditions. These 
results can be explained by the different mechanisms of HIF-1α regulation. Hypoxia controls 
HIF-1α mainly at post-translational level (44), while OSM-induced STAT3 signalling regulates 
HIF-1α at transcriptional level (8,43). HIF-1α activity is mainly negatively regulated at the 
protein level in an oxygen-dependant manner. While HIF-1α protein is stabilized under 
hypoxic conditions in consequence of down-regulation of PHD activity, it is continuously 
degraded via prolyl hydroxylation and VHL-mediated proteasomal degradation at 
physiological oxygen conditions. OSM signalling, however, does not contribute to an 
increased HIF-1α stability, as seen under hypoxia, but induces increased transcription of 
HIF-1α (8).  
Because hypoxia enhances HIF-1α protein stability, I investigated whether under normoxia 
OSM stimulation changes cellular metabolism towards a hypoxia-like metabolic phenotype in 
the human hepatocyte cell line PH5CH8. 
In this thesis, I showed that OSM stimulation slightly increases glucose uptake, lactate 
secretion, and reduces the influx of glucose-derived carbon in the TCA cycle under 
normoxia. It is well known that cancer cells increase their nutrient uptake to produce 
essential macromolecules (e.g., nucleotides, amino acids, and lipids) to sustain rapid growth 
and proliferation (20). Demaria and colleagues demonstrated that lactate production and 
glucose uptake are significantly increased in mouse embryonic fibroblasts, expressing 
constitutively active STAT3 (45). In contrast to the study by Demaria and colleagues using 
constitutively active STAT3, I studied a transient OSM-mediated STAT3 induction that 
resulted only in minor increase of glucose uptake and lactate production. In addition, they 
showed that several known HIF-1α target genes are up-regulated in response to STAT3 
signalling, including glucose transporter and two key glycolytic enzymes, phospho-
fructokinase and enolase 1 (45). As a result of an increased glycolytic flux, glycolytic 
intermediates accumulate that are essential for the synthesis of amino acids or to fuel the 
pentose phosphate pathway for nucleotide synthesis and generation of reducing equivalents 
(20,45). For example, high glucose turnover provides ribose-5-phosphate, serine and glycine 
for amino acid and nucleotide synthesis (20). 
Another study, done by Ando and coworkers, showed that IL-6 induced STAT3 signalling 
enhances glycolysis through increased expression of the glycolytic enzymes hexokinase 2 
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and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 in mouse embryonic fibroblasts 
(46). 
In my work, I demonstrated that the reduced glucose carbon contribution to the TCA cycle 
upon OSM stimulation is mediated via reduced PDH activity. In line with decreased PDH 
activity, I observed increased PDK1 expression. PDK1 is an important regulator of central 
carbon metabolism, because it can phosphorylate the mitochondrial PDH E1α subunit, 
thereby, inactivating its catalytic domain (17). In consequence, the entry of glucose-derived 
pyruvate into the TCA cycle is drastically decreased, thus limiting oxidative phosphorylation 
and promoting a higher conversion of pyruvate to lactate. These results highlight the role of 
PDK1 as an important enzyme, responsible for the OSM-induced metabolic phenotype. In 
line with these findings, Demaria and colleagues showed that in mouse embryonic 
fibroblasts, expressing constitutively active STAT3, PDK1 expression is increased. As a 
result, mitochondrial PDH activity is reduced and the amount of pyruvate-derived acetyl-CoA 
entering the citric acid cycle is limited (45). Moreover, Jung-whan and colleagues showed 
that PDK1 is a direct target of HIF-1α, critical for the maintenance of ATP levels and 
adaptation to hypoxia in MEFs and human Burkitt’s lymphoma cell line (17). In order to 
validate PDH inhibition via PDK1 up-regulation in response to OSM stimulation, it will be of 
interest to further analyse the degree of phosphorylation of PDH E1α subunit by Western 
Blot.  
Together with a decreased PDH flux, I showed that under normoxia, glutamine oxidation was 
also reduced upon OSM stimulation. Decreased glutamine oxidation in combination with an 
increase in glutamine-derived carbon in citrate, suggested that in OSM-stimulated cells, 
citrate is derived from glutamine through an alternative, non-oxidative pathway. At 21% O2 
cells usually synthesize citrate through oxidation of both glucose and glutamine. Since citrate 
is an important metabolite required to transport acetyl-CoA from mitochondria to the cytosol 
for fatty acid synthesis, cancer and proliferating cells carefully adapt cellular metabolism to 
maintain the citrate pool for proliferation, growth and survival (26). Because citrate production 
from glucose-derived acetyl-CoA was drastically reduced via PDH inhibition in OSM 
stimulated cells, PH5CH8 cells increased synthesis of citrate through reductive carboxylation 
of α-ketoglutarate (47). This pathway, often called reductive flux, can synthesize citrate solely 
from glutamine and CO2 without the necessity of pyruvate-derived acetyl-CoA and has been 
shown to be of special importance under hypoxia for lipid synthesis (18). These findings are 
in line with a study by Fendt and colleagues showing that as a result of reduced glucose and 
glutamine oxidation, the intracellular citrate levels decreased, triggering reductive α-
ketoglutarate carboxylation by mass action (19). 
Taken together, these data show that OSM treatment leads to increased aerobic glycolysis 
under normoxia (Warburg effect), characterized by an increased glucose uptake, increased 
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lactate production, and reduced glucose oxidation. Reduced pyruvate entry into the TCA 
cycle, led to increased reductive carboxylation of α-ketoglutarate, which is in line with a study 
by Gameiro et al, showing that impaired mitochondrial pyruvate oxidation triggers reductive 
glutamine metabolism (48). Collectively, these results highlight the importance of PDK1 as a 
key enzyme, responsible for the OSM-induced metabolic reprogramming. 
 
The Warburg effect, which is characterized by high glycolytic rates and reduced glucose 
oxidation under normoxia, is often associated with increased cellular proliferation (20). 
However, I did not observe any effect of OSM stimulation on the proliferation rate of PH5CH8 
cells, although I showed that OSM stimulation clearly induces a Warburg-like metabolic 
phenotype. PH5CH8 are immortalized human hepatocytes, and therefore proliferating cells, 
suggesting that the effect of OSM stimulation is not sufficient to further increase their 
proliferation rate. Recent studies showed that the role of IL-6 and STAT in tumour cells 
varies with each type of cancer (40). While cell proliferation was increased in multiple human 
myeloma cell lines and hepatocytes (40), cell cycle progression was inhibited in HepG2 cells 
in response to OSM and IL-6 signalling (49). Nevertheless, OSM-induced HIF-1α up-
regulation, and thus, metabolic reprogramming clearly supports increased proliferation rates 
and might provide a selective growth advantage. 
 
In order to investigate whether the OSM-induced metabolic reprogramming is comparable to 
the metabolic phenotype induced by hypoxia, I additionally examined the effect of hypoxia 
and OSM stimulation under hypoxia on central carbon metabolism. HIF-1α is known as a 
common link between adaptations to decreased O2, cancer cell metabolism, and cancer cell 
progression. HIF-1α regulates metabolic enzymes and other key factors involved in 
glycolysis and oxidative phosphorylation under hypoxic conditions (19). Generally, hypoxia 
induces similar effects as OSM stimulation under normoxia, including increased glucose 
uptake, increased lactate production, decreased glucose and glutamine oxidation, increased 
PDK1 expression and consequently decreased PDH activity, and increased reductive 
carboxylation of α-ketoglutarate. However, the changes induced by hypoxia were much more 
pronounced compared to the changes induced by OSM treatment under normoxia. Under 
hypoxia I did not observe any effects of OSM stimulation on central carbon metabolism. 
Hypoxia completely masked the effect of OSM treatment, most probably because at 1% O2 
the amount of transcriptionally active HIF-1α cannot be further induced through OSM 
treatment. Altogether, I demonstrated that OSM-treatment under normoxia induces an 
intermediate metabolic phenotype between hypoxia and normoxia in the human hepatocyte 
cell line PH5CH8.  
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Finally, I demonstrated that HIF-1α is critical for the OSM-mediated metabolic 
reprogramming in PH5CH8 cells. Silencing HIF-1α resulted in highly reduced HIF-1α mRNA 
and protein levels under normoxia and almost completely impeded the OSM-dependent 
suppression of glucose and glutamine oxidation. In line with these results, HIF-1α silencing 
resulted in decreased PDK1 mRNA levels, and in consequence PDH activity was not 
affected by OSM-stimulation at 21% O2. These results highlight the importance of HIF-1α as 
a transcriptional activator of PDK1, thereby indirectly regulating the activity of PDH and in 
consequence redirecting glucose away from oxidative phosphorylation and towards lactate 
production. In addition, the OSM-dependant increase of reductive glutamine metabolism was 
almost completely impaired in HIF-1α silenced cells.  
Collectively, these data show that HIF-1α expression is critical for the OSM-dependent shift 
from oxidative phosphorylation to a more glycolytic metabolism.  
Although O2 supply was highly limited under hypoxia, silencing of HIF-1α resulted in 
increased glucose and glutamine oxidation. These results strongly suggest that under 
hypoxia PDH inhibition, and therefore, limited acetyl-CoA availability via PDK1 up-regulation 
is the limiting factor for respiration and not reduced O2 availability.  
In this context, HIF-1 provides a common link between O2 availability, cancer metabolism, 
and inflammation. Hypoxic and inflammatory conditions have been associated to promote 
cancer development by altering cellular metabolism (26,27). In particular, IL-6-type cytokines 
have been shown to be key players in the regulation of cancer development and progression 
(2). Here, I showed that aberrant OSM-mediated HIF-1α up-regulation in immortalized 
human hepatocytes leads to metabolic changes similar to changes induced by tumours. For 
this reason, cellular metabolism might provide a causal link between chronic inflammation 
and malignant cellular transformation. However, it is still debated whether these metabolic 
changes are a consequence or a cause of carcinogenesis (28). 
Since HIF-1α is an important regulator of many metabolic genes, it will be of interest to 
further identify transcription factors downstream of HIF-1α that mediate the OSM-induced 
signal transduction and regulation of central carbon metabolism. Recently, it has been shown 
that PKM2 mediates the Warburg effect in macrophages (25). In this thesis, I did not observe 
a significant difference in PKM2 expression upon OSM treatment. However, PKM2 might be 
regulated post-translational thereby changing its conformation (23). In the cytoplasm, PKM2 
is present as tetramer and mediates the conversion of PEP to pyruvate, while in the nucleus 
PKM2 is a monomer and functions as kinase phosphorylating histone H3. Most probably the 
OSM-induced HIF-1α up-regulation under normoxia is not sufficient to increase PKM2 
transcription. In contrast to normoxia, PKM2 transcription was increased under hypoxia, but 
was not affected by OSM stimulation. In hypoxic cells, HIF-1α activates PKM2 transcription 
by binding to HRE. Thereby, PKM2 mediates increased glycolytic rates and probably 
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enhances glucose uptake, lactate production. Recently it has been shown that PKM2 
interacts with HIF-1α in the nucleus and functions as a transcriptional co-activator to 
stimulate the expression of HIF-1 target genes including glucose transporter 1, LDHA, and 
PDK1 in HeLa cervical carcinoma and Hep3B hepatoblastoma cells (24).  
In order to validate these findings, it would be interesting to analyse uptake and secretion 
rates, fluxes of central carbon metabolism and expression of glycolytic enzymes in another 
immortalized liver cancer cell line. As PDK1 is an important key enzyme, responsible for the 
OSM-induced metabolic reprogramming, it will be of interest to analyse the effect of PDK1 
knockdown in PH5CH8 cells. 
Since glucose-derived acetyl-CoA is reduced upon OSM stimulation, it will be of further 
interest to investigate whether it is compensated by an alternative acetyl-CoA source, 
including fatty acid oxidation or branched chain amino acids degradation.  
Cancer cells, which are highly proliferating cells, require large amounts of lipids for 
proliferation21. Therefore I would further investigate the effect of OSM and HIF-1α on fatty 
acid synthesis, including palmitate, a major constituent of cellular membranes.  
In this thesis I studied the effect of transient OSM-induced STAT3 signalling, it will be 
interesting to investigate how long-term activity of the JAK/STAT3 signalling pathway or 
constitutively active HIF-1α affects glycolytic enzymes (e.g. GLUT, PDK1, PKM2), glucose 
uptake and lactate secretion and central carbon metabolism of hepatocyte under normoxic 
conditions.  
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6 Appendix 
Supplemental Table 1. MID from [U-13C6]glucose under normoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GLC
M0 0,8310 0,0183 0,8739 0,0068 0,7713 0,0082 0,7896 0,0094
M1 0,0130 0,0021 0,0061 0,0010 0,0182 0,0008 0,0151 0,0010
M2 0,1079 0,0100 0,0705 0,0045 0,1341 0,0045 0,1227 0,0043
M3 0,0435 0,0050 0,0465 0,0009 0,0647 0,0022 0,0626 0,0034
M4 0,0051 0,0011 0,0034 0,0004 0,0121 0,0006 0,0105 0,0008
M0 0,1161 0,0217 0,1900 0,1582 0,1539 0,0224 0,0909 0,0202
M1 0,0101 0,0027 0,0069 0,0028 0,0111 0,0024 0,0051 0,0005
M2 0,0353 0,0009 0,0319 0,0062 0,0348 0,0014 0,0356 0,0007
M3 0,8429 0,0232 0,7754 0,1502 0,8045 0,0226 0,8727 0,0202
M0 0,8533 0,0075 0,8995 0,0204 0,7757 0,0030 0,7098 0,2479
M1 0,0067 0,0012 0,0034 0,0005 0,0092 0,0007 0,0933 0,1471
M2 0,1273 0,0161 0,0899 0,0070 0,1535 0,0061 0,1838 0,0566
M3 0,0140 0,0026 0,0077 0,0008 0,0254 0,0011 0,0185 0,0080
M4 00,0035 0,0297 00,0021 0,0208 0,0307 0,0008 00,0135 0,0469
M5 0,0031 0,0007 0,0026 0,0005 0,0087 0,0019 0,0073 0,0067
M0 0,8941 0,0239 0,9201 0,0022 0,8445 0,0061 0,8574 0,0252
M1 0,0016 0,0019 00,0005 0,0004 0,0060 0,0006 0,0046 0,0020
M2 0,0826 0,0149 0,0642 0,0020 0,1061 0,0050 0,0994 0,0170
M3 0,0162 0,0045 0,0099 0,0008 0,0307 0,0016 0,0271 0,0053
M4 0,0073 0,0028 0,0071 0,0014 0,0143 0,0011 0,0130 0,0012
M0 0,8277 0,0142 0,8266 0,0062 0,8677 0,0074 0,8771 0,0065
M1 0,0481 0,0060 0,0464 0,0020 0,0301 0,0027 0,0286 0,0022
M2 0,0285 0,0029 0,0262 0,0011 0,0193 0,0014 0,0173 0,0012
M3 0,0969 0,0053 0,1021 0,0034 0,0840 0,0033 0,0779 0,0033
M0 0,0750 0,0208 0,0571 0,0059 0,0698 0,0114 0,0858 0,0261
M1 0,0031 0,0002 0,0028 0,0000 0,0035 0,0002 0,0030 0,0003
M2 0,0395 0,0011 0,0402 0,0004 0,0404 0,0005 0,0398 0,0012
M3 0,8851 0,0191 0,9022 0,0056 0,8891 0,0108 0,8729 0,0245
M0 0,8379 0,0176 0,8754 0,0045 0,7897 0,0100 0,8072 0,0101
M1 0,0251 0,0067 0,0176 0,0032 0,0314 0,0046 0,0265 0,0033
M2 0,0940 0,0124 0,0629 0,0059 0,1127 0,0104 0,1070 0,0094
M3 0,0388 0,0051 0,0413 0,0008 0,0555 0,0035 0,0506 0,0025
M4 0,0052 0,0015 0,0037 0,0001 0,0125 0,0009 0,0097 0,0012
M0 0,9305 0,0077 0,9317 0,0099 0,9453 0,0035 0,9504 0,0062
M1 0,0007 0,0005 0,0010 0,0003 00,0003 0,0002 00,0001 0,0005
M2 0,0692 0,0071 0,0675 0,0097 0,0553 0,0034 0,0501 0,0057
M0 0,8468 0,0200 0,8945 0,0095 0,7916 0,0079 0,8099 0,0098
M1 0,0039 0,0013 0,0007 0,0006 0,0064 0,0002 0,0053 0,0005
M2 0,1181 0,0126 0,0853 0,0066 0,1420 0,0051 0,1314 0,0059
M3 0,0128 0,0026 0,0072 0,0009 0,0226 0,0012 0,0197 0,0014
M4 0,0155 0,0028 0,0098 0,0010 0,0296 0,0014 0,0267 0,0017
M5 0,0035 0,0009 0,0029 0,0003 0,0091 0,0005 0,0081 0,0007
M0 0,3603 0,0286 0,5258 0,0127 0,3327 0,0162 0,3666 0,0198
M1 0,0205 0,0011 0,0111 0,0004 0,0206 0,0011 0,0184 0,0012
M2 0,4845 0,0074 0,3676 0,0074 0,4455 0,0025 0,4287 0,0100
M3 0,0200 0,0027 0,0149 0,0003 0,0323 0,0013 0,0292 0,0016
M4 0,0830 0,0078 0,0511 0,0032 0,1107 0,0031 0,1007 0,0057
M5 0,0338 0,0044 0,0286 0,0013 0,0552 0,0020 0,0540 0,0039
M6 0,0016 0,0045 0,0029 0,0008 0,0080 0,0068 0,0069 0,0046
M0 0,8284 0,0175 0,8762 0,0083 0,7729 0,0081 0,7939 0,0072
M1 0,0144 0,0017 0,0069 0,0010 0,0196 0,0008 0,0165 0,0007
M2 0,1100 0,0097 0,0704 0,0050 0,1355 0,0041 0,1252 0,0041
M3 0,0420 0,0051 0,0429 0,0019 0,0602 0,0027 0,0541 0,0020
M4 0,0054 0,0011 0,0039 0,0004 0,0121 0,0006 0,0106 0,0005
M0 0,9989 0,0013 0,9978 0,0003 0,9999 0,0015 1,0020 0,0085
M1 00,0036 0,0007 00,0030 0,0004 00,0039 0,0006 00,0035 0,0007
M2 00,0008 0,0001 00,0010 0,0003 00,0007 0,0003 00,0005 0,0000
M3 00,0002 0,0003 00,0002 0,0003 00,0004 0,0002 00,0004 0,0009
M4 0,0090 0,0007 0,0098 0,0007 0,0081 0,0007 0,0044 0,0096
M5 00,0030 0,0002 00,0032 0,0002 00,0028 0,0002 00,0019 0,0023
Methionine_320
Malate_419
Pyruvate_174
Glutamate_432
Succinate_289
Serine_390
Lactate_261
Fumarate_287
Glycine_246
a0Ketoglutarate_346
CitricEacid_591
Aspartate_418
average stdev average stdev
Metabolites mass/
isotopomers average stdev average stdev
siCtrl siCtrl+OSM siHIF81α/ siHIF81α+OSM
 54 
Supplemental Table 2. MID from [U-13C5]glutamine under normoxia. 
 
 
 
 
M0 0,0711 0,0024 0,0883 0,0022 0,0932 0,0053 0,0897 0,0061
M1 0,0407 0,0023 0,0255 0,0001 0,0572 0,0055 0,0484 0,0025
M2 0,1356 0,0036 0,1093 0,0002 0,1492 0,0073 0,1383 0,0034
M3 0,1849 0,0023 0,2609 0,0008 0,1554 0,0034 0,1774 0,0027
M4 0,5749 0,0060 0,5229 0,0026 0,5520 0,0150 0,5531 0,0098
M0 0,9750 0,0015 0,9811 0,0016 0,9734 0,0024 0,9780 0,0038
M1 0,0022 0,0007 0,0012 0,0005 0,0057 0,0031 0,0044 0,0036
M2 0,0044 0,0003 0,0038 0,0003 0,0045 0,0003 0,0037 0,0003
M3 0,0190 0,0010 0,0142 0,0008 0,0176 0,0004 0,0148 0,0015
M0 0,0574 0,0298 0,0793 0,0332 0,0508 0,0046 0,0635 0,0278
M1 0,0367 0,0174 0,0492 0,0206 0,0371 0,0047 0,0405 0,0164
M2 0,0390 0,0134 0,0466 0,0195 0,0433 0,0034 0,0441 0,0104
M3 0,1063 0,0431 0,0731 0,0205 0,1472 0,0080 0,1083 0,0424
M4 0,0481 0,0072 0,0415 0,0041 0,0398 0,0004 0,0474 0,0101
M5 0,7240 0,0283 0,7218 0,0589 0,6878 0,0204 0,7078 0,0259
M0 0,4249 0,0514 0,3342 0,0460 0,3766 0,0533 0,3727 0,0316
M1 0,0173 0,0007 0,0125 0,0008 0,0313 0,0046 0,0272 0,0034
M2 0,0818 0,0053 0,0743 0,0044 0,1003 0,0087 0,0934 0,0070
M3 0,0238 0,0024 0,0270 0,0021 0,0248 0,0018 0,0248 0,0010
M4 0,4549 0,0438 0,5556 0,0391 0,4718 0,0459 0,4846 0,0211
M0 1,0064 0,0005 1,0066 0,0005 1,0070 0,0001 1,0067 0,0004
M1 00,0051 0,0004 00,0051 0,0003 00,0054 0,0002 00,0053 0,0001
M2 00,0012 0,0001 00,0013 0,0002 00,0014 0,0002 00,0012 0,0002
M3 0,0000 0,0001 0,0000 0,0000 00,0001 0,0001 0,0000 0,0001
M0 0,9776 0,0006 0,9840 0,0004 0,9825 0,0006 0,9833 0,0015
M1 0,0012 0,0004 0,0009 0,0002 0,0000 0,0005 0,0009 0,0009
M2 0,0047 0,0001 0,0038 0,0001 0,0038 0,0003 0,0038 0,0004
M3 0,0169 0,0001 0,0116 0,0002 0,0139 0,0003 0,0123 0,0003
M0 0,1384 0,0036 0,1194 0,0011 0,1563 0,0073 0,1476 0,0040
M1 0,1043 0,0027 0,0900 0,0008 0,1178 0,0055 0,1113 0,0030
M2 0,0984 0,0025 0,0849 0,0008 0,1111 0,0052 0,1050 0,0028
M3 0,1583 0,0030 0,2288 0,0004 0,1346 0,0042 0,1528 0,0027
M4 0,5009 0,0056 0,4776 0,0021 0,4803 0,0138 0,4839 0,0081
M0 1,0013 0,0004 1,0007 0,0001 1,0024 0,0005 1,0016 0,0001
M1 00,0021 0,0002 00,0016 0,0001 00,0028 0,0003 00,0023 0,0002
M2 0,0010 0,0002 0,0011 0,0001 0,0006 0,0002 0,0009 0,0001
M0 0,0299 0,0016 0,0311 0,0006 0,0454 0,0037 0,0432 0,0016
M1 0,0190 0,0015 0,0113 0,0001 0,0310 0,0043 0,0254 0,0019
M2 0,0324 0,0015 0,0276 0,0002 0,0399 0,0034 0,0361 0,0016
M3 0,1186 0,0040 0,0868 0,0007 0,1321 0,0090 0,1179 0,0041
M4 0,0403 0,0003 0,0416 0,0000 0,0377 0,0007 0,0389 0,0005
M5 0,7651 0,0079 0,8071 0,0013 0,7188 0,0199 0,7441 0,0088
M0 0,0723 0,0012 0,0811 0,0059 0,1050 0,0136 0,1095 0,0163
M1 0,0419 0,0015 0,0281 0,0004 0,0655 0,0041 0,0581 0,0030
M2 0,1118 0,0022 0,0840 0,0003 0,1271 0,0042 0,1162 0,0040
M3 0,1453 0,0012 0,1456 0,0014 0,1299 0,0006 0,1338 0,0022
M4 0,3716 0,0041 0,2720 0,0023 0,3327 0,0040 0,3130 0,0056
M5 0,2325 0,0056 0,3727 0,0018 0,2210 0,0162 0,2527 0,0123
M6 0,0284 0,0006 0,0187 0,0001 0,0208 0,0016 0,0199 0,0017
M0 0,0728 0,0027 0,0933 0,0025 0,0905 0,0062 0,0863 0,0052
M1 0,0424 0,0024 0,0266 0,0003 0,0587 0,0052 0,0503 0,0025
M2 0,1394 0,0032 0,1104 0,0003 0,1525 0,0064 0,1421 0,0032
M3 0,1842 0,0022 0,2557 0,0000 0,1541 0,0030 0,1740 0,0020
M4 0,5675 0,0060 0,5199 0,0023 0,5501 0,0149 0,5535 0,0092
M0 1,0094 0,0036 1,0061 0,0006 1,0104 0,0030 1,0069 0,0010
M1 00,0039 0,0004 00,0034 0,0006 00,0043 0,0005 00,0040 0,0002
M2 00,0004 0,0001 00,0010 0,0000 00,0011 0,0006 00,0006 0,0004
M3 00,0010 0,0005 00,0008 0,0001 00,0010 0,0003 00,0013 0,0008
M4 00,0046 0,0038 00,0002 0,0000 00,0046 0,0037 00,0004 0,0002
M5 0,0002 0,0009 00,0008 0,0000 0,0002 0,0009 00,0007 0,0002
a0Ketoglutarate_346
CitricEacid_591
Aspartate_418
Methionine_320
average
Pyruvate_174
Glutamate_432
Succinate_289
Serine_390
Lactate_261
Fumarate_287
mass/
isotopomers
Malate_419
stdev average stdev
Metabolites
Glycine_246
siCtrl siCtrl+OSM siHIF81α/ siHIF81α+OSM
stdev average stdev average
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Supplemental Table 3. MID from [U-13C6]glucose under hypoxia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M0 0,9004 0,0089 0,8671 0,0235 0,8471 0,0006 0,8391 0,0017
M1 -0,0042 0,0003 -0,0045 0,0007 0,0050 0,0009 0,0046 0,0011
M2 0,0188 0,0014 0,0206 0,0003 0,0669 0,0039 0,0686 0,0027
M3 0,0866 0,0109 0,1195 0,0253 0,0782 0,0052 0,0850 0,0025
M4 -0,0005 0,0004 -0,0008 0,0004 0,0045 0,0009 0,0045 0,0003
M0 0,0481 0,0037 0,0439 0,0081 0,0616 0,0177 0,0468 0,0032
M1 0,0016 0,0000 0,0016 0,0001 0,0019 0,0001 0,0019 0,0001
M2 0,0308 0,0003 0,0315 0,0005 0,0305 0,0008 0,0310 0,0001
M3 0,9201 0,0043 0,9229 0,0074 0,9068 0,0162 0,9210 0,0030
M0 1,0054 0,0006 1,0042 0,0001 1,0104 0,0059 1,0065 0,0008
M1 -0,0049 0,0003 -0,0041 0,0002 -0,0098 0,0067 -0,0057 0,0013
M2 -0,0011 0,0002 -0,0009 0,0003 -0,0008 0,0006 -0,0011 0,0005
M3 -0,0003 0,0003 -0,0002 0,0001 -0,0002 0,0002 -0,0002 0,0001
M4 0,0023 0,0004 0,0025 0,0005 0,0015 0,0001 0,0018 0,0002
M5 -0,0015 0,0001 -0,0015 0,0001 -0,0013 0,0000 -0,0013 0,0000
M0 0,9910 0,0037 0,9858 0,0011 0,9393 0,0123 0,9275 0,0059
M1 -0,0041 0,0005 -0,0028 0,0005 0,0006 0,0008 0,0004 0,0007
M2 0,0063 0,0029 0,0056 0,0019 0,0396 0,0067 0,0449 0,0049
M3 0,0008 0,0004 0,0008 0,0003 0,0097 0,0016 0,0103 0,0009
M4 0,0077 0,0007 0,0136 0,0035 0,0131 0,0017 0,0186 0,0005
M0 0,0974 0,0110 0,0766 0,0140 0,0956 0,0068 0,1043 0,0065
M1 0,0005 0,0000 0,0006 0,0000 0,0010 0,0001 0,0009 0,0002
M2 0,0274 0,0001 0,0280 0,0003 0,0277 0,0003 0,0273 0,0001
M3 0,8789 0,0107 0,8987 0,0135 0,8797 0,0065 0,8719 0,0066
M0 0,9483 0,0066 0,9456 0,0070 0,9316 0,0042 0,9457
M1 0,0144 0,0030 0,0133 0,0028 0,0203 0,0011 0,0124
M2 0,0046 0,0025 0,0032 0,0057 0,0301 0,0034 0,0236
M3 0,0467 0,0046 0,0534 0,0055 0,0303 0,0029 0,0300
M4 -0,0132 0,0012 -0,0145 0,0016 -0,0121 0,0009 -0,0114
M0 0,9581 0,0056 0,9588 0,0059 0,9681 0,0006 0,9688 0,0011
M1 -0,0001 0,0002 0,0001 0,0001 -0,0009 0,0001 -0,0008 0,0000
M2 0,0423 0,0056 0,0414 0,0058 0,0330 0,0007 0,0325 0,0008
M0 0,9778 0,0018 0,9767 0,0032 0,8813 0,0023 0,8582 0,0029
M1 0,0037 0,0004 0,0033 0,0003 0,0058 0,0001 0,0063 0,0004
M2 0,0161 0,0021 0,0155 0,0024 0,0923 0,0040 0,1008 0,0045
M3 0,0025 0,0001 0,0027 0,0002 0,0137 0,0011 0,0147 0,0011
M4 0,0011 0,0001 0,0013 0,0002 0,0159 0,0010 0,0164 0,0006
M5 -0,0016 0,0019 0,0008 0,0001 -0,0112 0,0019 0,0056 0,0014
M0 0,9197 0,0033 0,8954 0,0062 0,8704 0,0075 0,8611 0,0010
M1 -0,0028 0,0005 -0,0027 0,0005 0,0073 0,0008 0,0070 0,0005
M2 0,0192 0,0015 0,0209 0,0009 0,0706 0,0037 0,0737 0,0014
M3 0,0595 0,0027 0,0734 0,0010 0,0426 0,0040 0,0473 0,0021
M4 0,0052 0,0015 0,0144 0,0071 0,0100 0,0011 0,0118 0,0013
M0 0,9685 0,0045 0,9685 0,0063 0,6720 0,0318 0,6418 0,0060
M1 -0,0095 0,0014 -0,0095 0,0007 0,0008 0,0019 0,0018 0,0004
M2 0,0361 0,0049 0,0350 0,0061 0,2309 0,0173 0,2564 0,0070
M3 0,0102 0,0007 0,0114 0,0003 0,0178 0,0012 0,0192 0,0005
M4 0,0042 0,0005 0,0042 0,0006 0,0471 0,0048 0,0490 0,0017
M5 -0,0121 0,0007 -0,0123 0,0007 0,0375 0,0047 0,0409 0,0045
M6 0,0022 0,0001 0,0023 0,0001 -0,0007 0,0008 -0,0021 0,0004
M0 0,9939 0,0014 0,9935 0,0009 0,8738 0,0057 0,8691 0,0084
M1 -0,0042 0,0002 -0,0041 0,0000 0,0003 0,0007 0,0006 0,0008
M2 0,0119 0,0015 0,0118 0,0015 0,0799 0,0043 0,0877 0,0047
M3 0,0032 0,0002 0,0039 0,0006 0,0122 0,0007 0,0125 0,0005
M4 -0,0053 0,0002 -0,0055 0,0000 0,0299 0,0007 0,0260 0,0022
M5 0,0003 0,0000 0,0003 0,0000 0,0047 0,0009 0,0050 0,0002
M0 0,9232 0,0128 0,9356 0,0140 0,9507 0,0010 0,9492 0,0027
M1 0,0154 0,0035 0,0118 0,0034 0,0068 0,0004 0,0073 0,0003
M2 0,0113 0,0021 0,0087 0,0020 0,0069 0,0003 0,0070 0,0003
M3 0,0505 0,0073 0,0444 0,0087 0,0360 0,0002 0,0369 0,0021
M0 0,1440 0,0138 0,1814 0,0048 0,1767 0,0243 0,1712 0,0085
M1 0,0035 0,0002 0,0030 0,0002 0,0041 0,0002 0,0041 0,0002
M2 0,0280 0,0006 0,0270 0,0001 0,0274 0,0012 0,0274 0,0005
M3 0,8285 0,0133 0,7924 0,0047 0,7953 0,0229 0,8007 0,0083
siCtrl siCtrl+OSM siHIF.1α1 siHIF.1α+OSM
Metabolites mass1
isotopomers average stdev average stdev
Methionine_320
average stdev average stdev
Malate_419
Lactate_261
Succinate_289
Pyruvate_174
Fumarate_287
Glycine_246
Glutamate_432
Aspartate_418
CitricFacid_591
a-Ketoglutarate_346
Serine_390
Alanine_260
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Supplemental Table 4. MID from [U-13C5]glutamine under hypoxia. 
 
M0 0,1885 0,0033 0,2016 0,0066 0,1562 0,0000 0,1663 0,0016
M1 0,0075 0,0001 0,0065 0,0005 0,0334 0,0038 0,0282 0,0008
M2 0,0732 0,0020 0,0771 0,0026 0,1126 0,0058 0,1081 0,0002
M3 0,3567 0,0098 0,3841 0,0024 0,2224 0,0019 0,2473 0,0026
M4 0,3789 0,0087 0,3352 0,0071 0,4814 0,0077 0,4557 0,0038
M0 0,9866 0,0019 0,9861 0,0000 0,9823 0,0005 0,9863 0,0009
M1 0,0024 0,0003 0,0027 0,0002 0,0029 0,0004 0,0026 0,0002
M2 0,0039 0,0002 0,0041 0,0000 0,0043 0,0001 0,0038 0,0001
M3 0,0081 0,0005 0,0073 0,0002 0,0106 0,0008 0,0079 0,0001
M0 1,0055 0,0008 1,0061 0,0005 1,0061 0,0002 1,0064 0,0009
M1 -0,0032 0,0009 -0,0038 0,0006 -0,0043 0,0003 -0,0040 0,0008
M2 -0,0009 0,0002 -0,0009 0,0002 -0,0006 0,0000 -0,0010 0,0001
M3 -0,0006 0,0003 -0,0005 0,0001 -0,0003 0,0001 -0,0004 0,0000
M4 -0,0001 0,0000 -0,0001 0,0001 -0,0002 0,0000 -0,0001 0,0000
M5 -0,0009 0,0000 -0,0009 0,0000 -0,0009 0,0000 -0,0009 0,0000
M0 0,4959 0,1199 0,4762 0,0069 0,5527 0,0313 0,4052 0,1895
M1 -0,0023 0,0020 -0,0005 0,0007 0,0132 0,0027 0,0171 0,0075
M2 0,0237 0,0054 0,0264 0,0021 0,0608 0,0080 0,0809 0,0285
M3 0,0182 0,0031 0,0191 0,0002 0,0162 0,0008 0,0198 0,0040
M4 0,4672 0,1098 0,4816 0,0103 0,3592 0,0195 0,4795 0,1508
M0 0,9912 0,0008 0,9940 0,0019 0,9876 0,0002 0,9922 0,0013
M1 -0,0026 0,0003 -0,0022 0,0004 -0,0015 0,0001 -0,0023 0,0004
M2 0,0028 0,0001 0,0023 0,0005 0,0031 0,0000 0,0024 0,0001
M3 0,0087 0,0002 0,0062 0,0019 0,0110 0,0006 0,0084 0,0001
M0 0,1173 0,0026 0,1296 0,0049 0,1477 0,0062 0,1474 0,0047
M1 0,0884 0,0019 0,0977 0,0037 0,1113 0,0047 0,1111 0,0035
M2 0,0834 0,0018 0,0922 0,0035 0,1050 0,0044 0,1048 0,0033
M3 0,3350 0,0069 0,3662 0,0049 0,1963 0,0041 0,2235 0,0014
M4 0,3770 0,0132 0,3144 0,0073 0,4409 0,0115 0,4144 0,0109
M0 1,0000 0,0003 0,9998 0,0007 0,9998 0,0001 0,9984 0,0028
M1 -0,0015 0,0004 -0,0011 0,0006 -0,0013 0,0000 -0,0011 0,0007
M2 0,0019 0,0001 0,0017 0,0002 0,0018 0,0001 0,0030 0,0021
M0 0,0421 0,0039 0,0546 0,0150 0,0730 0,0001 0,0768 0,0007
M1 0,0015 0,0002 0,0018 0,0004 0,0237 0,0032 0,0215 0,0001
M2 0,0155 0,0006 0,0175 0,0018 0,0378 0,0025 0,0409 0,0010
M3 0,0331 0,0008 0,0331 0,0022 0,1142 0,0080 0,1103 0,0009
M4 0,0428 0,0012 0,0426 0,0005 0,0344 0,0015 0,0354 0,0011
M5 0,8680 0,0052 0,8530 0,0204 0,7200 0,0123 0,7178 0,0029
M0 0,2402 0,0619 0,3776 0,1654 0,1535 0,0046 0,1731 0,0023
M1 0,0085 0,0013 0,0054 0,0029 0,0356 0,0035 0,0314 0,0007
M2 0,0696 0,0044 0,0609 0,0138 0,1155 0,0057 0,1111 0,0003
M3 0,3272 0,0192 0,2934 0,0771 0,2141 0,0007 0,2318 0,0044
M4 0,3585 0,0378 0,2658 0,0725 0,4863 0,0042 0,4575 0,0013
M0 0,0990 0,0125 0,1024 0,0044 0,1487 0,0087 0,1456 0,0096
M1 0,0043 0,0005 0,0047 0,0001 0,0407 0,0055 0,0350 0,0015
M2 0,0315 0,0009 0,0356 0,0022 0,0879 0,0068 0,0898 0,0025
M3 0,0616 0,0007 0,0641 0,0026 0,1304 0,0058 0,1378 0,0049
M4 0,0819 0,0010 0,0791 0,0011 0,2057 0,0046 0,2011 0,0053
M5 0,7175 0,0127 0,7112 0,0089 0,3767 0,0139 0,3813 0,0017
M6 0,0076 0,0007 0,0064 0,0016 0,0119 0,0000 0,0113 0,0000
M0 0,0367 0,0006 0,0393 0,0043 0,0683 0,0000 0,0710 0,0017
M1 0,0021 0,0001 0,0020 0,0001 0,0206 0,0031 0,0181 0,0005
M2 0,0149 0,0005 0,0170 0,0018 0,0369 0,0023 0,0385 0,0004
M3 0,0303 0,0009 0,0303 0,0023 0,1063 0,0083 0,1017 0,0018
M4 0,0395 0,0005 0,0396 0,0006 0,0330 0,0010 0,0334 0,0000
M5 0,8826 0,0007 0,8774 0,0091 0,7399 0,0127 0,7425 0,0012
M0 1,0039 0,0005 1,0040 0,0002 1,0034 0,0001 1,0036 0,0012
M1 -0,0037 0,0004 -0,0037 0,0003 -0,0033 0,0001 -0,0033 0,0007
M2 0,0000 0,0001 -0,0001 0,0000 0,0001 0,0000 0,0001 0,0006
M3 -0,0002 0,0000 -0,0001 0,0000 -0,0002 0,0000 -0,0002 0,0001
M0 0,9515 0,0051 0,9569 0,0105 0,9477 0,0027 0,9534 0,0013
M1 -0,0025 0,0001 -0,0023 0,0001 -0,0005 0,0001 -0,0017 0,0002
M2 0,0113 0,0010 0,0107 0,0021 0,0101 0,0003 0,0097 0,0004
M3 0,0400 0,0043 0,0350 0,0083 0,0431 0,0023 0,0388 0,0007
stdev
Glutamate_432
average stdev average stdev
Malate_419
Lactate_261
Metabolites mass/
isotopomers
siCtrl siCtrl+OSM siHIF81α/ siHIF81α+OSM
average stdev average
Methionine_320
Succinate_289
Pyruvate_174
Fumarate_287
Glycine_246
Aspartate_418
CitricFacid_591
a-Ketoglutarate_346
Serine_390
Alanine_260
